Page last updated: 2024-12-05

methoxsalen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methoxsalen, also known as 8-methoxypsoralen, is a naturally occurring furanocoumarin found in plants such as Ammi majus. It is used in the treatment of psoriasis and vitiligo, both of which are skin conditions. It acts by binding to DNA and inhibiting cell division. It is synthesized through a multi-step process that starts with the extraction of psoralen from the plant. This process involves a series of chemical reactions to introduce the methoxy group at the 8-position of the psoralen molecule. Methoxsalen is photoactive, meaning it becomes activated by exposure to ultraviolet (UV) light. This activation allows it to interact with DNA and inhibit cell division. Research into methoxsalen focuses on its potential applications in treating other skin diseases, improving its efficacy, and reducing its side effects. '

Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
AmmigenusA plant genus of the family APIACEAE that is the primary plant source of KHELLIN.[MeSH]ApiaceaeA large plant family in the order Apiales, also known as Umbelliferae. Most are aromatic herbs with alternate, feather-divided leaves that are sheathed at the base. The flowers often form a conspicuous flat-topped umbel. Each small individual flower is usually bisexual, with five sepals, five petals, and an enlarged disk at the base of the style. The fruits are ridged and are composed of two parts that split open at maturity.[MeSH]
PsoraleagenusA plant genus of the family FABACEAE that is a source of psoralen (FICUSIN).[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID4114
CHEMBL ID416
CHEBI ID18358
SCHEMBL ID19168
MeSH IDM0013600

Synonyms (252)

Synonym
AC-4259
MLS002303011
bdbm50041234
8-methoxy-4'',5'':6,7-furocoumarin
8-methoxy-[furano-3''.2'':6.7-coumarin]
8-methoxy-2'',3'',6,7-furocoumarin
BRD-K63430059-001-03-2
BRD-K63430059-001-06-5
ultra mop
6-hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone
9-methoxy-7h-furo[3,2-g][1]benzopyran-7-one
9-methoxy-7h-furo[3,2-g]chromen-7-one
uvadex
CHEBI:18358 ,
8-methoxy-4',5':6,7-furocoumarin
8-methoxy-2',3',6,7-furocoumarin
7h-furo[3,2-g][1]benzopyran-7-one, 9-methoxy-
8-methoxy(furano-3'.2':6.7-coumarin)
meladoxen
7h-furo[3, 9-methoxy-
8-methoxy-4',6,7-furocoumarin
meloxine
8-methoxypsoralene
methoxa-dome
8-methoxy-[furano-3'.2':6.7-coumarin]
8-methoxy-2',6,7-furocoumarin
wln: t c566 do lvoj bo1
xanthotoxine
nci-c55903
ammoidin
8-mop
new-meladinin
oxsoralen
nsc-45923
oxoralen
meladinine
8-mp
methoxalen
KBIO1_000763
DIVK1C_000763
NCI60_004085
SDCCGMLS-0042377.P002
9-(methyloxy)-7h-furo[3,2-g]chromen-7-one
methoxsalen, 8-
meladinin (van)
puvamet
5-benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone
oxsoralen ultra
ccris 2083
8-methoxy-(furano-3'.2':6.7-coumarin)
psoralon-mop
proralone-mop
9-methoxypsoralen
9-methoxy-7h-furo(3,2-g)(1)benzopyran-7-one
8-methoxypsoralen with ultraviolet a therapy
hsdb 2505
9-methoxyfuro(3,2-g)chromen-7-one
7h-furo(3,2-g)(1)benzopyran-7-one, 9-methoxy-
9-methoxy-7h-furo(3,2-g)benzopyran-7-one
einecs 206-066-9
7-furocoumarin
geroxalen
nsc 45923
methoxsalen plus ultraviolet radiation
oxsoralen-ultra
oxsoralen lotion
psoralen-mop
8-methoxy-4',5',6,7-furocoumarin
brn 0196453
zanthotoxin
methoxsalen (jp17/usp)
oxsoralen (tn)
uvadex (tn)
D00139
SPECTRUM_001023
PRESTWICK3_000479
methoxy-8-psoralen
PRESTWICK_661
cas-298-81-7
NCGC00016418-01
ACON1_000174
NCGC00178871-02
NCGC00178871-01
NCGC00178871-03
smr000071170
MLS000062633
SPECTRUM5_001891
BPBIO1_000680
IDI1_000763
PRESTWICK2_000479
MEGXP0_000095
BSPBIO_000618
NSC45923 ,
9-methoxyfuro[3,2-g]chromen-7-one
oxypsoralen
puvalen
ammodin
meladinin
NCGC00060938-02
8-methoxyfuranocoumarin
methoxsalen
o-methylxanthotoxol
C01864
298-81-7
8-methoxypsoralen
xanthotoxin
8-methoxypsoralen, analytical standard
DB00553
8MO ,
BSPBIO_001997
OPREA1_166319
NCGC00060938-03
NCGC00060938-04
NCGC00060938-06
KBIOSS_001503
KBIO2_001503
KBIO3_001497
KBIO2_004071
KBIOGR_000543
KBIO2_006639
SPECTRUM3_000499
SPECTRUM2_001052
SPECTRUM4_000052
PRESTWICK1_000479
PRESTWICK0_000479
NINDS_000763
SPBIO_001004
SPBIO_002557
SPECTRUM1500400
NCGC00060938-05
8 methoxypsoralen
HMS2091D20
AKOS000277012
CHEMBL416 ,
8-methoxsalen
metoxalen
vitpso
sm-88 component methoxsalen
HMS502G05
1246819-63-5
methoxsalen-13cd3
X0009 ,
HMS1920N05
HMS1569O20
STK735539
NCGC00016418-07
HMS3259L13
HMS2096O20
ST041029
9-methoxyfurano[3,2-g]chromen-2-one
EN300-52504
NCGC00256435-01
tox21_302816
dtxsid8020830 ,
dtxcid40830
NCGC00259316-01
tox21_201767
A820092
nsc-757114
nsc757114
pharmakon1600-01500400
tox21_110432
HMS2269P03
CCG-36366
NCGC00016418-08
NCGC00016418-02
NCGC00016418-04
NCGC00016418-11
NCGC00016418-03
NCGC00016418-06
NCGC00016418-09
NCGC00016418-12
NCGC00016418-10
NCGC00016418-05
metoxaleno
9-methoxyfuro[3,2-g][1]benzopyran-7-one
dltasoralen
methoxaten
FT-0671145
5-19-06-00015 (beilstein handbook reference)
u4vj29l7bq ,
unii-u4vj29l7bq
methoxsalen [usp:ban:jan]
FT-0602101
NCGC00016418-14
methoxsalen [usp monograph]
methoxsalen [mart.]
methoxsalen [mi]
methoxsalen [iarc]
methoxsalen [jan]
methoxsalen [who-dd]
methoxsalen [usp-rs]
methoxsalen [orange book]
methoxsalen [vandf]
methoxsalen [hsdb]
AM84906
S1952
HY-30151
CS-1983
NC00652
SCHEMBL19168
tox21_110432_1
NCGC00016418-15
AB00052042-14
AB00052042-15
deltapsoralen
methoxsalene
5-benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone
8-methoxy-6,7-furanocoumarin
9-methoxy-7h-furo[3,2-g]chromen-7-one #
Q-100381
AB00052042_17
AB00052042_16
mfcd00005009
8-methoxy-d3 psoralen
9-methoxy-2h-furo[3,2-g]chromen-2-one
SR-01000629727-4
sr-01000629727
SR-01000629727-2
xanthotoxin, analytical standard
methoxsalen, united states pharmacopeia (usp) reference standard
HMS3655B05
SBI-0051443.P003
SW167762-4
'9-methoxy-7h-furo[3,2-g][1]benzopyran-7-one'
8-methoxypsoralen;xanthotoxin;8-mop
xanthotoxin (methoxsalen)
DS-5159
Q408570
methoxsalen (oxsoralen)
12692-94-3
BCP28212
BRD-K63430059-001-09-9
HMS3884K16
9-methoxy-furo[3,2-g]chromen-7-one
8-mop;xanthotoxin;ammoidin
methoxsalen (8-methoxypsoralen)
8-methoxy psoralen
gtpl12457
oxoralen-ultra
8-methoxy(furano-3',2':6,7-coumarin)
methoxsalen (usp monograph)
methoxsalen (mart.)
methoxsalen (iarc)
5-benzofuranacrylic acide, 6-hydroxy-7-methoxy-, delta-lactone
9-methoxy-7h-furo(3,2-g)chromen-7-one
methoxsalen (usp-rs)
puvasoralen
methoxsalen (usp:ban:jan)
mopsoralen
methoxypsoralen
Z754918916

Research Excerpts

Overview

Methoxsalen (MTS) is a natural bioactive compound found in a variety of plants that has many known biofunctions. Its effects on osteoporosis and related mechanisms are not clear.

ExcerptReferenceRelevance
"Methoxsalen is a natural compound found in many seed plants. "( Effect of Methoxsalen on Ca²⁺ Homeostasis and Viability in Human Osteosarcoma Cells.
Chou, CT; Hsu, SS; Jan, CR; Kuo, CC; Liang, WZ; Lu, YC; Wang, JL, 2017
)
2.3
"Methoxsalen (MTS) is a natural bioactive compound found in a variety of plants that has many known biofunctions; however, its effects on osteoporosis and related mechanisms are not clear. "( Methoxsalen supplementation attenuates bone loss and inflammatory response in ovariectomized mice.
Choi, RY; Ham, JR; Hwang, YH; Kim, MJ; Lee, MK; Yee, ST, 2017
)
3.34
"Methoxsalen is a direct inhibitor and inhibited the activities (>90%) of all enzymes at a concentration of 300 µM except for CYP2C9."( Methoxsalen as an in vitro phenotyping tool in comparison with 1-aminobenzotriazole.
Ajjala, DR; Boggavarapu, RK; Manoharan, AK; Molgara, P; Nirogi, R; Palacharla, RC; Panthangi, HR; Ponnamaneni, RK, 2019
)
2.68

Effects

ExcerptReferenceRelevance
"Methoxsalen has been shown to be associated with premature cataract formation by forming adducts with lens proteins following oral administration and subsequent UVA exposure."( Methoxsalen-induced macular toxicity.
Maitray, A; Rishi, P, 2017
)
2.62

Actions

Methoxsalen (8-MOP) may cause important pharmacokinetic drug interactions as it has been shown to inhibit and/or induce several drug-metabolizing enzymes.

ExcerptReferenceRelevance
"Methoxsalen failed to increase I(sc)."( Psoralens: novel modulators of Cl- secretion.
Bridges, RJ; Devor, DC; Frizzell, RA; Singh, AK, 1997
)
1.02
"Methoxsalen (8-MOP) may cause important pharmacokinetic drug interactions as it has been shown to inhibit and/or induce several drug-metabolizing enzymes in vitro, in animal models and in humans."( Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients.
Fuhr, U; Scharffetter-Kochanek, K; Servera-Llaneras, M; Tantcheva-Poór, I, 2001
)
1.75

Treatment

Methoxsalen pretreatment prolonged the duration of nicotine-induced antinociception and hypothermia (15mg/kg, po) for periods up to 6- and 24-hr postnicotine administration. Pretreatment of methox salen significantly reduced tumor incidence from 93.8% to 16.7% (50 mg/kg) and 20.0%.

ExcerptReferenceRelevance
"Methoxsalen pretreatment prolonged the duration of nicotine-induced antinociception and hypothermia (15mg/kg, po) for periods up to 6- and 24-hr postnicotine administration, respectively."( Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor.
Alsharari, SD; Damaj, MI; Siu, EC; Tyndale, RF, 2014
)
1.34
"Methoxsalen pretreatment diminished area under the curve of plasma 7-hydroxycoumarin versus time by 24% (2.40 +/- 0.48 versus 3.20 +/- 0.55 microg."( Single-dose methoxsalen effects on human cytochrome P-450 2A6 activity.
Hankins, DC; Kharasch, ED; Taraday, JK, 2000
)
1.41
"Pretreatment of methoxsalen significantly reduced tumor incidence from 93.8% to 16.7% (50 mg/kg) and 20.0% (12.5 mg/kg), and tumor multiplicity from 5.97 to 0.23 (50 mg/kg) and 0.25 (12.5 mg/kg) tumors/mouse."( Pretreatment with 8-methoxypsoralen, a potent human CYP2A6 inhibitor, strongly inhibits lung tumorigenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in female A/J mice.
Ikeda, M; Imaida, K; Kamataki, T; Maeta, H; Miyazaki, M; Saoo, K; Takeuchi, H; Yamazaki, H; Yokohira, M, 2003
)
0.65
"Post-treatment with methoxsalen must be given early and is only partially effective in mice."( The drug methoxsalen, a suicide substrate for cytochrome P-450, decreases the metabolic activation, and prevents the hepatotoxicity, of carbon tetrachloride in mice.
Amouyal, G; Carrion-Pavlov, Y; Degott, C; Descatoire, V; Geneve, J; Labbe, G; Larrey, D; Letteron, P; Pessayre, D; Tinel, M, 1987
)
1
"Pretreatment with methoxsalen appears to decrease the metabolic activation of chloroform and essentially prevents its hepatotoxicity and nephrotoxicity in mice."( Methoxsalen decreases the metabolic activation and prevents the hepatotoxicity and nephrotoxicity of chloroform in mice.
Degott, C; Descatoire, V; Labbe, G; Larrey, D; Lettéron, P; Pessayre, D; Tinel, M, 1987
)
2.04

Toxicity

ExcerptReferenceRelevance
"The acute oral and intraperitoneal LD50 values of micronized 8-Methoxypsoralen were determined in rats and mice."( Acute toxicity of micronized 8-methoxypsoralen in rodents.
Apostolou, A; Comereski, CR; Williams, RE, 1979
)
0.26
" No organ toxicity was seen except for toxic liver changes when severe cutaneous burn and pronounced ulcerations were produced."( Dermal toxicity of 8-methoxypsoralen administered (by gavage) to hairless mice irradiated with long-wave ultraviolet light.
Glinski, W; Jablonska, S; Jarzabek-Chorzelska, M; Langner, A; Marzulli, FN; Pawinska, M; Wolska, H, 1977
)
0.26
"Thirty-nine patients with psoriasis undergoing PUVA participated in a prospective double-blind study of acute non-phototoxic adverse effects comparing the liquid formulations of 8-methoxypsoralen (0."( Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
Ferguson, J; George, SA, 1992
)
0.28
" These studies show that the psoralens with two potential DNA-binding sites (8-MOP and 5-MOP) were more toxic than psoralens with only one photoreactive site (5-MIP and 3-CEP)."( Toxicity of 8-methoxypsoralen, 5-methoxypsoralen, 3-carbethoxypsoralen, or 5-methylisopsoralen with ultraviolet radiation in the hairless (HRA/Skh) mouse.
Davies, RE; Dunnick, JK; Forbes, PD; Iverson, WO, 1987
)
0.27
" In this study, 8-MOP was administered to male and female Fischer 344 rats without subsequent UVA exposure for the determination of toxic effects of the psoralen alone."( Subchronic toxicity in rats administered oral 8-methoxypsoralen.
Davis, WE; Dunnick, JK; Jorgenson, TA; McConnell, EE; Rosen, VJ, 1984
)
0.27
"Phototoxicity is the most significant short-term adverse effect of PUVA therapy."( PUVA-induced phototoxicity: incidence and causes.
Beck, L; Marwaha, S; Morison, WL, 1997
)
0.3
"Phototoxicity is a common adverse effect, and patients should be warned of this potential occurrence."( PUVA-induced phototoxicity: incidence and causes.
Beck, L; Marwaha, S; Morison, WL, 1997
)
0.3
"0159 microg/mL with UV) while CLZ was negative up to a toxic concentration of 35 microg/mL."( Photoclastogenicity-an improved protocol, its validation, and investigation of the photogenotoxicity of DMBA.
Aardema, M; Lawlor, T; Murli, H; Spicer, C, 2002
)
0.31
" Safety was assessed using reports of adverse device effects (ADEs) and unanticipated ADEs (UADEs), device malfunctions and defects, vital signs, laboratory parameters and physical examinations."( Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma.
Bisaccia, E; Geskin, L; Vonderheid, EC, 2009
)
0.35
" carica have a significant toxic effect against early fourth-stage larvae of Aedes aegypti L with an lethal concentration (LC(50)) value of 10."( Immunotoxicity activity of natural furocoumarins from milky sap of Ficus carica L. against Aedes aegypti L.
Chung, IM; Kim, SJ; Moon, HI; Park, SW; Yeo, MA, 2011
)
0.37
", fungi that produce toxic aflatoxins."( Effects of a naturally occurring and a synthetic synergist on toxicity of three insecticides and a phytochemical to navel orangeworm (Lepidoptera: Pyralidae).
Berenbaum, MR; Lawrance, A; Niu, G; Pollock, HS; Siegel, JP, 2012
)
0.38
" In the oral administration study, both known phototoxic compounds and 5 drugs induced phototoxic reactions in both species; one compound each was found to be toxic only in SD rats or guinea pigs."( Evaluation of skin phototoxicity study using SD rats by transdermal and oral administration.
Hashimoto, K; Kataoka, A; Miyashita, T; Nejishima, H; Ogawa, H; Ohsumi, T; Yonezawa, Y, 2015
)
0.42
" Therefore, the method is not useful for screening of toxic or phototoxic effects either."( Comparison of various methods to analyse toxic effects in human skin explants: Rediscovery of TTC assay.
Cukr, M; Lichnovská, R; Rajnochová Svobodová, A; Ulrichová, J; Vostálová, J; Zálešák, B, 2018
)
0.48
" The phototoxicity of bergapten as a side effect should be further avoided."( Bergapten: A review of its pharmacology, pharmacokinetics, and toxicity.
Cao, Y; Dai, X; Li, X; Liang, Y; Liu, K; Lu, J; Wang, X; Xie, L; Zhang, X, 2021
)
0.62
" It was found that liposomes containing furanocoumarins of Sosnovsky's hogweed juice are more toxic for L929 cells in comparison with liposomal forms of pure substances 8-methoxypsoralen and 5-methoxypsoralen."( Evaluation of photocytotoxicity liposomal form of furanocoumarins Sosnowsky's hogweed.
Ageev, VP; Brodovskaya, EP; Kulikov, OA; Maev, IV; Petrov, PS; Pyataev, NA; Shlyapkina, VI; Sukhorukov, GB; Yakobson, DE; Zharkov, MN, 2022
)
0.72

Pharmacokinetics

Administration of intra peritoneal (ip) methoxsalen significantly increased nicotine's Cmax, prolonged the plasma half-life (fourfold decrease) and increased its area under the curve.

ExcerptReferenceRelevance
" Each subject underwent three pharmacokinetic studies after oral ingestion of 5-MOP (1."( Chronopharmacokinetics of 5-methoxypsoralen.
Agache, PG; Faivre, B; Humbert, P; Makki, S; Renaud, A; Treffel, P, 1990
)
0.28
"In order to register the inter- and intraindividual variability of serum levels of 8-methoxypsoralen (MOP) (Oxsoralen, n = 12; Geroxalen, n = 46; Mopsoralen, n = 30), we investigated a total of 1,276 serum samples obtained at 11 patient appointments over 8 h in 88 patients and compared the individual serum concentrations - time curves with the pharmacokinetic parameters Cmax (maximal serum concentration) on the time tmax, as well as the AUC value (area under the curve) as a parameter of bioavailability."( [Pharmacokinetic comparison of 3 8-methoxypsoralen preparations and clinical aspects].
Haustein, UF; Meyer, FP; Quednow, B; Walther, T, 1990
)
0.28
" The calculated pharmacokinetic parameters varied considerably between the different dogs."( Pharmacokinetics of 8-methoxypsoralen in the dog.
Belpaire, FM; Bogaert, MG; Braeckman, RA; Monbaliu, JG,
)
0.13
" Differences in response are often due to the unpredictable pharmacokinetic behaviour of the drug."( Clinical pharmacokinetics of methoxsalen and other psoralens.
de Wolff, FA; Thomas, TV,
)
0.42
"A pharmacokinetic comparison was carried out with 7 commercially available brands of 8-methoxypsoralen and 5 new formulations."( A pharmacokinetic comparison in dogs of seven brands of 8-MOP and five new formulations.
Adriaens, P; Daenens, P; De Greef, H; Kinget, R; Roelandts, R; Van Boven, M, 1985
)
0.27
" The pharmacokinetic parameters were determined by moment and compartmental population analysis, the latter performed with the program NONMEM."( The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans.
Barr, J; Billard, V; Corash, L; Gambus, PL; Minto, CF; Shafer, SL; Stickney, JL; Tessman, JW, 1995
)
0.29
" Concomitant intake of 8-MOP with metoclopramide did not significantly influence these 3 pharmacokinetic values."( Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
Fathi, M; Piletta, PA; Salomon, D; Saurat, JH; Studer-Sachsenberg, EM, 1997
)
0.3
" Associating 8-MOP with metoclopramide does not alter the pharmacokinetic values of 8-MOP and should not require any change in PUVA treatment."( Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
Fathi, M; Piletta, PA; Salomon, D; Saurat, JH; Studer-Sachsenberg, EM, 1997
)
0.3
" In serum, peak 8-MOP concentrations were reached < or =40 min following ingestion; the half-life of 8-MOP in the serum was 50+/-14 min (n=7)."( Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis.
Nestle, FO; Panizzon, R; Shephard, SE, 1999
)
0.3
"We conclude that interpretation of investigations on clinical success and dose-response aspects of ECP must take into account the complex pharmacokinetic behaviour of 8-MOP during the ECP procedure."( Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis.
Nestle, FO; Panizzon, R; Shephard, SE, 1999
)
0.3
" Pharmacokinetic behaviour of 8-MOP was examined in serum; samples were analysed by HPLC."( Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy.
Langguth, P; Panizzon, RG; Shephard, SE, 2001
)
0.31
"The peak of maximum 8-MOP concentration in blood was sharp, rapid and reproducible: tmax of 8-MOP in blood averaged 23+/-3 min, independent of the particular formulation."( Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy.
Langguth, P; Panizzon, RG; Shephard, SE, 2001
)
0.31
" In addition, we found that administration of methoxsalen significantly increased the plasma half-life of nicotine (approximately doubled) and increased its area under the curve compared with saline treatment."( Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice.
Damaj, MI; Martin, BR; Sellers, EM; Siu, EC; Tyndale, RF, 2007
)
0.6
" The rapid and sensitive method was fully validated and successfully applied to the pharmacokinetic study of pimpinellin, isopimpinellin and phellopterin in rats following oral administration of Toddalia asiatica extract."( Simultaneous determination of pimpinellin, isopimpinellin and phellopterin in rat plasma by a validated UPLC-MS/MS and its application to a pharmacokinetic study after administration of Toddalia asiatica extract.
Jiang, M; Li, F; Liu, Z; Lu, X; Qin, F; Song, Y; Wen, J, 2012
)
0.38
" The method was successfully applied to a pharmacokinetic study of eight coumarins in rats after oral administration of radix angelicae pubescentis."( Simultaneous determination of scopoletin, psoralen, bergapten, xanthotoxin, columbianetin acetate, imperatorin, osthole and isoimperatorin in rat plasma by LC-MS/MS for pharmacokinetic studies following oral administration of Radix Angelicae Pubescentis e
Chang, YX; Deng, YR; Gao, XM; Guo, XR; He, J; Li, J; Ma, L; Zhang, BL; Zhang, L; Zhang, P; Zhang, QH, 2013
)
0.39
" For the pharmacokinetic analysis of serum, the mean (SD) values obtained for the bergapten were as follows: Cmax, 228."( Pharmacokinetic studies of bergapten in dog plasma by using a LC-MS/MS method studies.
Dong, CY; Gao, Y; Liu, YZ; Zhang, X; Zhang, XM; Zhou, Y, 2013
)
0.39
"Administration of intra peritoneal (ip) methoxsalen significantly increased nicotine's Cmax, prolonged the plasma half-life (fourfold decrease) of nicotine, and increased its area under the curve (AUC) compared with ip vehicle treatment."( Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor.
Alsharari, SD; Damaj, MI; Siu, EC; Tyndale, RF, 2014
)
0.88
"This study aimed to verify the applicability of a proposed photosafety screening system based on a reactive oxygen species (ROS) assay and a cassette-dosing pharmacokinetic (PK) study to chemicals with wide structural diversity."( Photochemical and Pharmacokinetic Characterization of Orally Administered Chemicals to Evaluate Phototoxic Risk.
Iyama, Y; Onoue, S; Sato, H; Seto, Y, 2019
)
0.51
" Moreover, pharmacokinetic studies showed that bergapten has higher absolute bioavailability and can cross the blood-brain barrier and has a great potential for treating brain disease, but the mechanism needs further clarification to make greater use of its ability to treat brain diseases."( Bergapten: A review of its pharmacology, pharmacokinetics, and toxicity.
Cao, Y; Dai, X; Li, X; Liang, Y; Liu, K; Lu, J; Wang, X; Xie, L; Zhang, X, 2021
)
0.62

Compound-Compound Interactions

ExcerptReferenceRelevance
"In a randomized, double-blind comparative study 60 patients with severe, widespread psoriasis were treated either with photochemotherapy (PUVA) alone or in combination with acitretin."( Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study.
Fritsch, P; Geiger, JM; Guggenbichler, A; Hönigsmann, H; Tanew, A, 1991
)
0.28
"1% 8-methoxypsoralen (8-MOP) cream was also tested in combination with SSR."( Treatment with topical khellin in combination with ultraviolet A or solar-simulated radiation is carcinogenic to lightly pigmented hairless mice.
Bech-Thomsen, N; Wulf, HC,
)
0.13
"To study the inhibitory effects of Etoposide (VP16) combined with 8-methoxypsoralen (8-MOP) on human highly metastatic mucoepidermoid carcinoma cells (Mc3)."( [Inhibitory Effects of Etoposide Combined with 8-methoxypsoral en on Highly Metastatic Human Mucoepidermoid Carcinoma Cells].
Han, J; Li, Y; Liu, B; Situ, Z; Wu, J, 1999
)
0.3
" The comet tail lengths of epidermal cells of the mice were statistically significantly increased for all three fluoroquinolones (FQ) tested in combination with UV irradiation."( Photo-chemically induced DNA effects in the comet assay with epidermal cells of SKH-1 mice after a single oral administration of different fluoroquinolones and 8-methoxypsoralen in combination with exposure to UVA.
Gross-Tholl, N; Herbold, B; von Keutz, E; Wirnitzer, U, 2006
)
0.33
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"Acitretin is currently used alone or combined with PUVA (psoralen + UVA) or with narrow-band ultraviolet B (NBUVB), to treat moderate and severe psoriasis."( Cytotoxic and genotoxic effects of acitretin, alone or in combination with psoralen-ultraviolet A or narrow-band ultraviolet B-therapy in psoriatic patients.
Bronze-da-Rocha, E; Custódio, JB; Fernandes, JC; Figueiredo, A; Moreiras, A; Oliveira, H; Rocha-Pereira, P; Santos-Silva, A; Silva, FS, 2013
)
0.39
" Drugs were selected based not only on the knowledge that the 6-hydroxylation of exogenous melatonin, its principal pathway of metabolism, is mainly mediated by hepatic CYP1A2, but also on the likelihood of the drug being concurrently administered with melatonin."( Potential drug interactions with melatonin.
Ioannides, C; Papagiannidou, E; Skene, DJ, 2014
)
0.4

Bioavailability

There is considerable interindividual variation in bioavailability of Methoxsalen (8-methoxypsoralen) after ingestion of the standard dose used in photochemotherapy. The soft-capsule formulation resulted in a 59% increase in extent of absorption.

ExcerptReferenceRelevance
"Significant improvement in the effective bioavailability of methoxsalen was achieved when it was administered to rats and dogs in a solution as compared to a suspension."( Improved delivery of methoxsalen.
Higuchi, T; Kreuter, J, 1979
)
0.82
"05) under nonfasting compared to fasting conditions, indicating higher relative bioavailability of the drug in the presence of food."( Effect of food on kinetics of 8-methoxsalen.
Ehrnebo, M; Ehrsson, H; Nilsson, SO; Wallin, I; Wennersten, G, 1979
)
0.54
" Bioavailability and phototoxicity of 5-MOP were compared."( A new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement.
Agache, P; Humbert, P; Khaldoun, H; Makki, S; Treffel, P, 1992
)
0.28
" Single oral doses of 14C-5-methoxypsoralen (5-MOP) to human subjects (50 mg), rats (1 mg/kg) and dogs (1 mg/kg) were fairly well absorbed but subjected to extensive first-pass metabolism, at least in rat and human."( Metabolism of the anti-psoriatic agent 5-methoxypsoralen in humans: comparison with rat and dog.
Chasseaud, LF; Forlot, P; John, BA; Wood, SG, 1992
)
0.28
" In contrast with in vitro experiments, photobinding of CPZ to epidermal DNA/RNA was not found in vivo; apparently the bioavailability in the nucleus is very low."( Photobinding of 8-methoxypsoralen, 4,6,4'-trimethylangelicin and chlorpromazine to Wistar rat epidermal biomacromolecules in vivo.
Beijersbergen van Henegouwen, GM; Caffieri, S; Dall'Acqua, F; Persons, CC; Schoonderwoerd, SA, 1991
)
0.28
" Whether concomitant retinoid administration influences the bioavailability of 8-MOP was considered an interesting question."( [Influence of retinoids on the bioavailability of methoxy-8-psoralen].
Amblard, P; Beani, JC; Beriel, H; Berthod, F; Boitard, M; Bonnot, D; Reymond, JL, 1991
)
0.28
" Experiments on suction blister fluids taken from patients after topical treatment with BO containing 5-MOP indicate that in comparison with water the bioavailability and thus the genotoxic effects of the compounds are decreased."( Genotoxicity of bergapten and bergamot oil in Saccharomyces cerevisiae.
Averbeck, D; Averbeck, S; Dubertret, L; Morlière, P; Young, AR, 1990
)
0.28
" With a new liquid preparation of 5-MOP we have now extended our earlier investigation on a larger clinical scale and have correlated the clinical response with the bioavailability of the drug."( 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
Hönigsmann, H; Ortel, B; Rappersberger, K; Tanew, A, 1988
)
0.27
"The absolute bioavailability of 8-methoxypsoralen in gelatin capsules and as a solution was studied in dogs."( Study of the bioavailability of different formulations of 8-methoxypsoralen in the dog.
Belpaire, FM; Bogaert, MG; Monbaliu, JG,
)
0.13
" The bioavailability of 5-MOP was significantly lower than that of 8-MOP in all tissues analyzed."( Kinetics of 8-methoxypsoralen and 5-methoxypsoralen distribution in guinea pig serum, epidermis and ocular lens.
Giles, A; Kornhauser, A; Wamer, W, 1987
)
0.27
" The soft-capsule formulation resulted in a 59% increase in extent of absorption and in a greater rate of absorption of methoxsalen than from the hard capsule."( Bioavailability of a new oral methoxsalen formulation. A serum concentration and photosensitivity response study.
Kouba, RF; Maiwald, DC; Sullivan, TJ; Walter, JL, 1986
)
0.77
"A bioavailability study was performed with a pill containing microcrystalline 8-MOP and a soft gelatine capsule containing dissolved 8-MOP in 35 patients receiving PUVA treatment."( Bioavailability study of two different 8-methoxypsoralen (8-MOP) preparations in patients receiving PUVA therapy.
Hueg, B; Nørgaard, M; Staberg, B, 1985
)
0.27
" Bioavailability and phototoxicity were compared."( Comparison of bioavailability and phototoxicity of two oral preparations of 5-methoxypsoralen.
Cormane, RH; Siddiqui, AH; Stolk, LM; Westerhof, W, 1985
)
0.27
" 8-MOP is taken with breakfast; four types of breakfast were available, which differed by their lipid content; this study showed that the diet has no influence on the bioavailability of 8-MOP."( Influence of the diet on the plasma kinetics of 8-methoxypsoralen.
Amblard, P; Beani, JC; Beriel, H; Boitard, M; Bonnot, D; Reymond, JL, 1985
)
0.27
" These results indicate a different bioavailability of 8-MOP in water and in interstitial fluid containing proteins."( Photobiological activity of suction blister fluid from patients treated with 8-methoxypsoralen.
Averbeck, D; Blais, J; Dubertret, L; Prognon, P; Vigny, P, 1983
)
0.27
"The bioavailability of two galenic formulations of 5-methoxypsoralen (5-MOP) is described."( [5-Methoxypsoralen: bioavailability and pharmacokinetics].
Mascher, H; Nitsche, V, 1982
)
0.26
" 2 Bioavailability and serum peak concentrations were significantly higher for Maladinine in all patients and the MPD value favoured Maladinine in 5 of the 8 patients."( Difference in bioavailability between two brands of 8-methoxypsoralen and its impact on the clinical response in psoriatic patients.
De Wolff, FA; Herfst, MJ, 1982
)
0.26
" In one patient who showed a lower absorption rate of 8-MOP plasma levels varied from 0-126 ng/ml."( Intraindividual variations of 8-methoxypsoralen plasma levels.
Korting, HC; Schäfer-Korting, M, 1982
)
0.26
" The advantages of this modality include noninvolvement of the upper gastrointestinal tract, high bioavailability of psoralen, peak levels at a predictable time, and rapid elimination of the drug."( Microenema of 8-methoxypsoralen in photochemotherapy of psoriasis.
Cormane, RH; Kammeijer, A; Korthals Altes-Levij van Vinninghe, HR; Siddiqui, AH; Stolk, L, 1982
)
0.26
" The results of this study are discussed in view of susceptibility to oxidation, epidermal bioavailability and metabolic activation."( UV radiation protecting efficacy of cysteine derivatives, studies with UVA-induced binding of 8-MOP and CPZ to rat epidermal biomacromolecules in vivo.
Beijersbergen van Henegouwen, GM; Van den Broeke, LT, 1995
)
0.29
" The food had a dramatic effect on the bioavailability of 5-MOP."( Food-induced increase in bioavailability of 5-methoxypsoralen.
Berg, M; Ehrsson, H; Eksborg, S; Ros, AM; Wallin, I, 1994
)
0.29
"Previous studies have shown important inter- and intraindividual variations in bioavailability of 8-methoxypsoralen (8-MOP) under the influence of factors that are not yet known with certainty."( Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
Fathi, M; Piletta, PA; Salomon, D; Saurat, JH; Studer-Sachsenberg, EM, 1997
)
0.3
"The purpose of this study was to investigate a possible effect of metoclopramide on the bioavailability of 8-MOP since these drugs are frequently combined to prevent nausea, a common side effect of systemic 8-MOP."( Influence of metoclopramide on the pharmacokinetics of 8-methoxypsoralen.
Fathi, M; Piletta, PA; Salomon, D; Saurat, JH; Studer-Sachsenberg, EM, 1997
)
0.3
"Administration of 8-methoxypsoralen (8-MOP) in a dilute bath water solution is an effective therapeutic alternative to oral PUVA therapy, avoiding systemic side effects, offering better bioavailability of the psoralen and requiring much smaller amounts of UVA for induction of therapeutic effects."( Plasma levels of 8-methoxypsoralen following PUVA-bath photochemotherapy.
Altmeyer, P; Hoffmann, K; Kerscher, M; von Kobyletzki, G,
)
0.13
"Conventional oral PUVA therapy is hampered by large inter- and intraindividual variations in the bioavailability of 8-methoxypsoralen (8-MOP), caused by its low solubility in the gastrointestinal juices and large interindividual differences in hepatic metabolism rate (hepatic first pass)."( Pharmacokinetic behaviour of sublingually administered 8-methoxypsoralen for PUVA therapy.
Langguth, P; Panizzon, RG; Shephard, SE, 2001
)
0.31
"There is considerable interindividual variation in bioavailability of Methoxsalen (8-methoxypsoralen) after ingestion of the standard dose used in photochemotherapy (psoralen plus ultraviolet A)."( The effect of methoxsalen dose on ultraviolet-A-induced erythema.
Dawe, RS; Farr, PM; Ibbotson, SH, 2001
)
0.91
" In this current study, cellular bioavailability of 8-MOP, TMA and CPZ was investigated in vitro, using low doses of UVA relevant for the clinical setting of ECP."( Phototoxicity, distribution and kinetics of association of UVA-activated chlorpromazine, 8-methoxypsoralen, and 4,6,4'-trimethylangelicin in Jurkat cells.
Dobrucki, J; Rajwa, B; Sarna, T; Skrzeczyńska-Moncznik, J; van Henegouwen, GB; Wolnicka-Głubisz, A, 2005
)
0.33
"Furanocoumarins increase the bioavailability of drugs that are CYP3A4 substrates."( Drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine.
Bouwer, M; Goosen, TC; Rheeders, M, 2006
)
0.57
" Our results suggest that inhibiting nicotine metabolism can be used to dramatically enhance nicotine's bioavailability and its resulting pharmacology, which further supports this inhibitory approach for clinical development of an oral nicotine replacement therapy."( Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor.
Alsharari, SD; Damaj, MI; Siu, EC; Tyndale, RF, 2014
)
0.62
" However, the poor water solubility, low stability and limited bioavailability have prevented the use of BEO in cancer therapy."( Anticancer activity of liposomal bergamot essential oil (BEO) on human neuroblastoma cells.
Britti, D; Carafa, M; Celia, C; Di Marzio, L; Locatelli, M; Morittu, VM; Navarra, M; Paolino, D; Trapasso, E; Ventura, CA; Wolfram, J, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" In the present study we examined the bioavailability of 8-MOP when different plastic materials and solvents are used as matrices."( Matrix-dependent absorption of 8-methoxypsoralen in extracorporeal photopheresis.
Ahrens, N; Burkhardt, R; Graf, B; Gruber, M; Hähnel, V; Tuemmler, S; Weber, I, 2020
)
0.56
" Moreover, pharmacokinetic studies showed that bergapten has higher absolute bioavailability and can cross the blood-brain barrier and has a great potential for treating brain disease, but the mechanism needs further clarification to make greater use of its ability to treat brain diseases."( Bergapten: A review of its pharmacology, pharmacokinetics, and toxicity.
Cao, Y; Dai, X; Li, X; Liang, Y; Liu, K; Lu, J; Wang, X; Xie, L; Zhang, X, 2021
)
0.62

Dosage Studied

ExcerptRelevanceReference
" Following the dosage parameters toxic side effects were rare and reversible."( [Oral photochemotherapy (author's transl)].
Gschnait, F, 1977
)
0.26
" In general the magnitude of this induced variation increased with increasing dosage of the mutagen."( Induced quantitative variation for penicillin titre in clonal populations of Aspergillus nidulans.
Caten, CE; Simpson, IN, 1979
)
0.26
" The UVB erythema response of normal skin served as the guide to light dosage in the same manner as administration of the Goeckerman regimen."( Topical methoxsalen administration and sunlamp fluorescent irradiation in psoriasis.
Barton, JO; de los Reyes, O; Kligman, A; Petrozzi, JW, 1979
)
0.69
" We used higher doses of 8-MOP, starting with 50 mg, and increased the dosage further in 15 cases."( Photochemotherapy of psoriasis (PUVA) without specialized equipment.
Kligman, AM; Petrozzi, JW, 1978
)
0.26
" However, with high dosage of UVA (5 J/cm(2)) with and without 8-MOP still 25-30% cells migrated through the filters."( Leukocyte chemotaxis after in vitro treatment with 8-methoxypsoralen and UVA.
Christophers, E; Langner, A, 1977
)
0.26
" Although a high chemical concentration and low dosage of UVA was a less time-consuming method of inducing phototoxicity, our results indicate that lower concentration and longer UVA exposure were less likely to induce undersirable blistering reactions."( Factors influencing methoxsalen phototoxicity in vitiliginous skin.
Arora, SK; Willis, I, 1976
)
0.58
" The high incidence of adverse effects suggests that current dosage recommendations be reviewed."( Liquid formulations of 8-methoxypsoralen (8-MOP) and 5-MOP: a prospective double-blind crossover assessment of acute non-phototoxic adverse effects.
Ferguson, J; George, SA, 1992
)
0.28
" The whole-body concentrations of hexobarbital (100 mg/kg dose) in mice 30 min after dosing were 14."( Inhibition and induction of drug metabolism by psoralens: alterations in duration of sleep induced by hexobarbital and in clearance of caffeine and hexobarbital in mice.
Apseloff, G; Gerber, N; Hilliard, JB; Mays, DC, 1991
)
0.28
" There was a great interindividually different first-pass effect for 8-MOP in dependence on the galenic formulation of the 8-MOP brand; therefore, the change to another 8-MOP brand with a modern galenic formulation led only to a slight increase of serum levels, and consequently an increase in the 8-MOP dosage was necessary."( 8-Methoxypsoralen serum levels in poor responders to photochemotherapy. Importance of drug formulation and individual factors.
Haustein, UF; Walther, T, 1991
)
0.28
" The resulting erythema was measured objectively 72 h after irradiation and dose-response curves for psoralen-UVA erythema were constructed."( The relationship between plasma psoralen concentration and psoralen-UVA erythema.
Cox, NH; Diffey, BL; Farr, PM; Fisher, C; Mclelland, J, 1991
)
0.28
" The partial phenotypic correction of the two end points examined is interpreted as indicating either a gene dosage effect or the necessity of introducing more than one gene type in order to achieve complete recovery of a normal phenotype."( Partial complementation of the Fanconi anemia defect upon transfection by heterologous DNA. Phenotypic dissociation of chromosomal and cellular hypersensitivity to DNA cross-linking agents.
Diatloff-Zito, C; Heddle, J; Moustacchi, E; Rosselli, F, 1990
)
0.28
" The smallest ultraviolet radiation doses to produce erythema (minimal erythema dose and minimal phototoxic dose, respectively) were recorded and dose-response curves were constructed for UVB (24 hours after irradiation) and PUVA (48 hours) using objective measurement."( A comparison of the dose-response relationship for psoralen-UVA erythema and UVB erythema.
Cox, NH; Diffey, BL; Farr, PM, 1989
)
0.28
"Ten patients with chronic widespread plaque psoriasis, all of whom had previously completely cleared and suffered a subsequent widespread relapse after conventional PUVA therapy, were treated with a modified UVA dosage schedule, with psoralen formulation and dosage unchanged."( A modified dosage schedule for increased efficiency in PUVA treatment of psoriasis.
Carabott, FM; Hawk, JL, 1989
)
0.28
" An examination of the dose-response relationship between 8-MOP concentration and UVA dose indicated that properties such as 8-MOP photoadduct formation and PHA response are proportional to the combined doses of these two factors."( Molecular aspects of extracorporeal photochemotherapy.
Dall'Amico, R; Gasparro, FP; Goldminz, D; Simmons, E; Weingold, D,
)
0.13
" However, these finding as well as some hematological and serum electrolyte changes lacked a dose-response relationship."( Toxicity of 8-methoxypsoralen in cynomolgous monkeys (Macaca fascicularis).
Brickl, R; Leuschner, F; Rozman, K; Rozman, T, 1989
)
0.28
" When administered in the same dosage as 8-MOP, 5-MOP turned out to be significantly less effective; however, by doubling the oral dosage, comparable results in terms of clearing of psoriasis were obtained."( 5-Methoxypsoralen (Bergapten) for photochemotherapy. Bioavailability, phototoxicity, and clinical efficacy in psoriasis of a new drug preparation.
Hönigsmann, H; Ortel, B; Rappersberger, K; Tanew, A, 1988
)
0.27
" Dose-response curves for 5-MOP and 8-MOP obtained under standardized conditions demonstrated a linear relationship between the diameter of growth inhibition zones and the logarithm of the psoralen concentration in the range from 1 to 400 micrograms/ml."( The Candida phototoxicity test. The sensitivity of different strains and species of Candida, standardization attempts and analysis of the dose-response curves for 5- and 8-methoxypsoralen.
Knudsen, EA, 1985
)
0.27
" Dose-response data for both survival and transformation were obtained as a function of 8-methoxypsoralen (8-MOP) concentration and UVA dose."( Neoplastic transformation of C3H mouse embryo 10T1/2 cells by 8-methoxypsoralen plus UVA radiation.
Ananthaswamy, HN, 1985
)
0.27
" An action spectrum, constructed from the dose-response regression lines, showed peak effectiveness at 335 nm."( An action spectrum for 8-methoxypsoralen-sensitized inhibition of DNA synthesis in vivo.
Kaidbey, KH, 1985
)
0.27
" The dose-response curve is steeper, with blistering reactions occurring in some subjects after as little as three to four times the minimum phototoxic dose of UV radiation at 320-400 nm (UVA)."( Cutaneous phototoxicity due to psoralens.
Gange, RW; Parrish, JA, 1984
)
0.27
" All test groups developed atypical squamous papillomas in direct proportion to the dosage of UVA radiation received."( Psoralen-containing sunscreen is tumorigenic in hairless mice.
Cartwright, LE; Walter, JF, 1983
)
0.27
" A suspension in soft gelatine capsules was tested against a micronized powder in hard gelatine capsules on six volunteers, both in a dosage of 40 mg."( [5-Methoxypsoralen: bioavailability and pharmacokinetics].
Mascher, H; Nitsche, V, 1982
)
0.26
" Above this concentration there were fewer dividing cells and an apparent departure from linearity in the dose-response curve."( Sister chromatid exchange frequency in human epidermal cells in culture treated with 8-methoxypsoralen and long-wave UV radiation.
Faed, MJ; Johansen, M; West, MR, 1982
)
0.26
"Exposure of cells to 8-methoxypsoralen plus a low dosage of UVA (365 nm) generates mainly monoadducts (PUVA-I treatment), while further irradiation of PUVA-I treated cells after removal of 8-methoxypsoralen (PUVA-II treatment) converts a high frequency of monoadducts to crosslinks."( Mutagenicity and specific mutation spectrum induced by 8-methoxypsoralen plus a low dose of UVA in the hprt gene in diploid human fibroblasts.
Chiou, CC; Yang, JL, 1995
)
0.29
"6 mg/kg) suggests that conventional psoralen dosing according to body weight is not ideal."( Improved prediction of the minimal phototoxic dose in PUVA therapy.
Farr, PM; Matthews, JN; Sakuntabhai, A, 1994
)
0.29
" Observations on the time-course and dose-response characteristics of PUVA erythema suggest that larger doses of UVA could be used safely, provided that the frequency of PUVA treatment is reduced."( Response of psoriasis to twice weekly PUVA.
Farr, PM; Sakuntabhai, A; Sharpe, GR, 1993
)
0.29
" The erythema responses were judged visually, and also measured using a reflectance instrument in order to construct dose-response curves."( PUVA erythemal sensitivity depends on plasma psoralen concentration and UVA sensitivity.
Diffey, BL; Farr, PM; Sakuntabhai, A, 1993
)
0.29
" The two different methods of dosing were used on consecutive treatment days and the plasma 8-MOP concentration was measured on each occasion 2 h after ingestion of the crystalline form of 8-MOP, given to the nearest 10 mg."( Calculation of 8-methoxypsoralen dose according to body surface area in PUVA treatment.
Diffey, BL; Farr, PM; Sakuntabhai, A, 1995
)
0.29
" The purpose of this study was to determine the pharmacokinetics and safety of 8-MOP administered intravenously in the bactericidal dosage range."( The pharmacokinetics of 8-methoxypsoralen following i.v. administration in humans.
Barr, J; Billard, V; Corash, L; Gambus, PL; Minto, CF; Shafer, SL; Stickney, JL; Tessman, JW, 1995
)
0.29
" The equimolar mixtures show an antimutagenic effect at both dosage used with a synergistic effect at lower dosage and an additive antimutagenic activity at higher dosage."( Effects of beta-carotene and alpha-tocopherol on photogenotoxicity induced by 8-methoxypsoralen: the role of oxygen.
Bianchi, L; Melli, R; Pizzala, R; Quarta, S; Rehak, L; Stivala, LA; Vannini, V, 1996
)
0.29
"We conclude that interpretation of investigations on clinical success and dose-response aspects of ECP must take into account the complex pharmacokinetic behaviour of 8-MOP during the ECP procedure."( Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis.
Nestle, FO; Panizzon, R; Shephard, SE, 1999
)
0.3
" Fourteen patients (all male) aged 38 to 72 years with CTCL of the mycosis fungoides type, stage IIa/IIb, and a 72-year-old male patient with a Ki-1 lymphoma were treated twice a month for 6 months with extracorporeal photochemotherapy using oral 8-methoxypsoralen as photosensitizer in combination with interferon alfa-2a subcutaneously 3 times a week in the maximal tolerable dosage (ie, up to 18 x 10(6) U)."( Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Hipler, UC; Knopf, B; Koch, HJ; Liebold, K; Looks, A; Meyer, J; Wollina, U, 2001
)
0.31
" The minimal phototoxic dose at 72 h was recorded, erythema was measured using a reflectance instrument, and dose-response curves were constructed."( The effect of methoxsalen dose on ultraviolet-A-induced erythema.
Dawe, RS; Farr, PM; Ibbotson, SH, 2001
)
0.67
"To understand the photobiological effects and to increase the safety and effectiveness of this novel topical PUVA therapy, we assessed the kinetics and dose-response of phototoxicity of 8-methoxypsoralen (8-MOP) cream in order to develop a treatment schedule for this treatment option."( Kinetics and dose-response of photosensitivity in cream psoralen plus ultraviolet A photochemotherapy: comparative in vivo studies after topical application of three standard preparations.
Grundmann-Kollmann, M; Kaufmann, R; Ludwig, R; Ochsendorf, FR; Podda, M; Tegeder, I; Zollner, TM, 2001
)
0.31
" In a dose-response study, four concentrations of 8-MOP cream (0."( Kinetics and dose-response of photosensitivity in cream psoralen plus ultraviolet A photochemotherapy: comparative in vivo studies after topical application of three standard preparations.
Grundmann-Kollmann, M; Kaufmann, R; Ludwig, R; Ochsendorf, FR; Podda, M; Tegeder, I; Zollner, TM, 2001
)
0.31
" To obtain dose-response relations the drug-induced effects on peak P'K and on the steady state value, kinfinity, were measured."( Effects of three alkoxypsoralens on voltage gated ion channels in Ranvier nodes.
Düring, T; Gerst, F; Hänsel, W; Koppenhöfer, E; Wulff, H, 2000
)
0.31
"We sought to determine the time-course and dose-response characteristics of erythema induced by topical TMP, and to compare these parameters with those for topical 8-methoxypsoralen (MOP) within patients."( An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen.
Dawe, RS; Ferguson, J; Ibbotson, SH; Man, I; McKinlay, J, 2003
)
0.32
" TMP PUVA had a significantly steeper dose-response curve at 48, 72, and 96 hours compared with 8-MOP PUVA."( An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen.
Dawe, RS; Ferguson, J; Ibbotson, SH; Man, I; McKinlay, J, 2003
)
0.32
" In view of the steeper dose-response curve for TMP PUVA, a lower UVA incremental regimen should be considered compared with that for 8-MOP PUVA."( An intraindividual comparative study of psoralen-UVA erythema induced by bath 8-methoxypsoralen and 4, 5', 8-trimethylpsoralen.
Dawe, RS; Ferguson, J; Ibbotson, SH; Man, I; McKinlay, J, 2003
)
0.32
" Seventy-two hours after UVA exposure minimal phototoxic doses (MPD) were defined visually and the intensity of the erythema response was also assessed by using a narrowband spectrophotometer The MPD and the dose-response curves for erythema response of the gels and creams were compared with those of the bath."( Phototoxicity of new psoralen-containing gels and creams versus bath PUVA.
Leenutaphong, V; Nimkulrat, P; Sudtim, S, 2005
)
0.33
" The slope of the dose-response curve for erythema of this preparation also significantly corresponded to that of the bath solution."( Phototoxicity of new psoralen-containing gels and creams versus bath PUVA.
Leenutaphong, V; Nimkulrat, P; Sudtim, S, 2005
)
0.33
" Additionally, methoxsalen potentiated nicotine-induced antinociception and hypothermia as evidenced by leftward shifts in nicotine's dose-response curve."( Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor.
Alsharari, SD; Damaj, MI; Siu, EC; Tyndale, RF, 2014
)
0.97
"Intravitreal (ITV) dosing has become a clinically important route of administration for the treatment of uveitis, endophthalmitis, retinal vein occlusion, diabetic macular edema and age-related macular degeneration."( Intravitreal administration of known phototoxicants in the rabbit fails to produce phototoxicity: implications for phototoxicity testing of intravitreally administered small molecule therapeutics.
Baker, JF; Bantseev, V; Brown, MH; Farman, C; Learn, DB; Schuetz, C; Thackaberry, EA, 2015
)
0.42
" dosage highly unlikely to have an effect on nocturia or any other pharmacologically significant effect in humans."( Investigations on the constituents of SagaPro tablets, a food supplement manufactured from
Eyjolfsson, R; Kowal, NM; Olafsdottir, ES, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
dermatologic drugA drug used to treat or prevent skin disorders or for the routine care of skin.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
photosensitizing agentA chemical compound that can be excited by light of a specific wavelength and subsequently transfer energy to a chosen reactant. This is commonly molecular oxygen within a cancer tissue, which is converted to (highly rective) singlet state oxygen. This rapidly reacts with any nearby biomolecules, ultimately killing the cancer cells.
cross-linking reagentA reagent with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between macromolecules, principally side chains of amino acids in proteins, allowing the locations of naturally reactive areas within the proteins to be identified.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
psoralensA furanocoumarin with a 7H-furo[3,2-g]chromen-7-one skeleton and its substituted derivatives thereof.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (57)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency52.01010.002541.796015,848.9004AID1347395; AID1347398
glp-1 receptor, partialHomo sapiens (human)Potency10.00000.01846.806014.1254AID624417
RAR-related orphan receptor gammaMus musculus (house mouse)Potency34.18900.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency23.12760.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency22.91050.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743035; AID743063
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency17.23610.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency19.49710.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency3.31730.001310.157742.8575AID1259253; AID1259256
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency52.52260.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency52.14160.000817.505159.3239AID1159527; AID1159531
pregnane X nuclear receptorHomo sapiens (human)Potency45.96800.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency19.80160.000229.305416,493.5996AID588514; AID743069; AID743075; AID743077; AID743078
GVesicular stomatitis virusPotency3.89020.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency4.36490.00108.379861.1304AID1645840
67.9K proteinVaccinia virusPotency1.35350.00018.4406100.0000AID720579; AID720580
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency30.83560.001024.504861.6448AID743212; AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency25.17890.023723.228263.5986AID588543; AID743223
aryl hydrocarbon receptorHomo sapiens (human)Potency0.31180.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency51.68650.001723.839378.1014AID743083
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency5.01190.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency5.01190.00255.840031.6228AID899
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
mitogen-activated protein kinase 1Homo sapiens (human)Potency5.01190.039816.784239.8107AID995
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency17.22890.000627.21521,122.0200AID720636
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency10.49610.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Interferon betaHomo sapiens (human)Potency3.89020.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Nuclear receptor ROR-gammaHomo sapiens (human)Potency13.33320.026622.448266.8242AID651802
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Guanine nucleotide-binding protein GHomo sapiens (human)Potency1.58491.995325.532750.1187AID624287
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
TAR DNA-binding protein 43Homo sapiens (human)Potency11.22021.778316.208135.4813AID652104
GABA theta subunitRattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency10.49611.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency3.89020.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)0.04000.00011.774010.0000AID625245
Cytochrome P450 2A6Homo sapiens (human)Ki0.98330.00561.52717.5000AID1209284; AID589223; AID589228
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)85.11000.00002.37899.7700AID260085
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)27.38000.00000.933210.0000AID360659; AID758230
Beta-secretase 1Homo sapiens (human)IC50 (µMol)500.00000.00061.619410.0000AID637774
Cytochrome P450 2A13Homo sapiens (human)Ki0.04000.04002.71005.6000AID1209283
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2A6Homo sapiens (human)Kd11.00000.68003.19506.2000AID1209278
Cytochrome P450 2A13Homo sapiens (human)Kd1.60000.43003.18008.2000AID1209287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (138)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
proteolysisBeta-secretase 1Homo sapiens (human)
membrane protein ectodomain proteolysisBeta-secretase 1Homo sapiens (human)
response to lead ionBeta-secretase 1Homo sapiens (human)
protein processingBeta-secretase 1Homo sapiens (human)
amyloid-beta formationBeta-secretase 1Homo sapiens (human)
amyloid precursor protein catabolic processBeta-secretase 1Homo sapiens (human)
positive regulation of neuron apoptotic processBeta-secretase 1Homo sapiens (human)
amyloid-beta metabolic processBeta-secretase 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painBeta-secretase 1Homo sapiens (human)
prepulse inhibitionBeta-secretase 1Homo sapiens (human)
cellular response to copper ionBeta-secretase 1Homo sapiens (human)
cellular response to manganese ionBeta-secretase 1Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionBeta-secretase 1Homo sapiens (human)
signaling receptor ligand precursor processingBeta-secretase 1Homo sapiens (human)
cellular response to amyloid-betaBeta-secretase 1Homo sapiens (human)
amyloid fibril formationBeta-secretase 1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A13Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 2A13Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A13Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A13Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (70)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
amyloid-beta bindingBeta-secretase 1Homo sapiens (human)
endopeptidase activityBeta-secretase 1Homo sapiens (human)
aspartic-type endopeptidase activityBeta-secretase 1Homo sapiens (human)
protein bindingBeta-secretase 1Homo sapiens (human)
peptidase activityBeta-secretase 1Homo sapiens (human)
beta-aspartyl-peptidase activityBeta-secretase 1Homo sapiens (human)
enzyme bindingBeta-secretase 1Homo sapiens (human)
protein serine/threonine kinase bindingBeta-secretase 1Homo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
monooxygenase activityCytochrome P450 2A13Homo sapiens (human)
iron ion bindingCytochrome P450 2A13Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A13Homo sapiens (human)
heme bindingCytochrome P450 2A13Homo sapiens (human)
aromatase activityCytochrome P450 2A13Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A13Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A13Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (56)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
lysosomeBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
early endosomeBeta-secretase 1Homo sapiens (human)
late endosomeBeta-secretase 1Homo sapiens (human)
multivesicular bodyBeta-secretase 1Homo sapiens (human)
endoplasmic reticulum lumenBeta-secretase 1Homo sapiens (human)
Golgi apparatusBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
synaptic vesicleBeta-secretase 1Homo sapiens (human)
cell surfaceBeta-secretase 1Homo sapiens (human)
endosome membraneBeta-secretase 1Homo sapiens (human)
membraneBeta-secretase 1Homo sapiens (human)
axonBeta-secretase 1Homo sapiens (human)
dendriteBeta-secretase 1Homo sapiens (human)
neuronal cell bodyBeta-secretase 1Homo sapiens (human)
membrane raftBeta-secretase 1Homo sapiens (human)
recycling endosomeBeta-secretase 1Homo sapiens (human)
Golgi-associated vesicle lumenBeta-secretase 1Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseBeta-secretase 1Homo sapiens (human)
endosomeBeta-secretase 1Homo sapiens (human)
plasma membraneBeta-secretase 1Homo sapiens (human)
trans-Golgi networkBeta-secretase 1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A13Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A13Homo sapiens (human)
cytoplasmCytochrome P450 2A13Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (425)

Assay IDTitleYearJournalArticle
AID1209283Mixed inhibition of CYP2A13 (unknown origin)2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
AID380314Phototoxicity against Streptococcus faecalis at 10 ug/disk in presence of cool-white fluorescent light
AID107810The IC50-UVA is the dose of UVA light which in the presence of fixed drug concentration (20 uM) is necessary to induce a 50% inhibition of clonal growth by incubation at the ground state by keeping mammalian cells in the dark1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Synthesis and biological activity of (hydroxymethyl)- and (diethylaminomethyl)benzopsoralens.
AID423858Photo-antiproliferative activity against human HeLa cells exposed to 365 nm, 0.793 Jcm'-2 UVA light2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
A new psoralen derivative with enlarged antiproliferative properties.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1103225Phytotoxicity against Lactuca sativa cv. Burpee's Iceberg (lettuce) assessed as reduction in chlorophyll content at 100 uM after 7 days by spectrophotometry2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID724347Cytotoxicity against human 1BR3 cells assessed as cell viability at 50 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID21302Solubility of compound in water1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID1103224Phytotoxicity against Lactuca sativa cv. Burpee's Iceberg (lettuce) assessed as reduction in chlorophyll content compound treated at 100 uM in darkness after 7 days followed by exposure to white light by spectrophotometry2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID724348Cytotoxicity against human 1BR3 cells assessed as cell viability at 100 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID497311Cytotoxicity against human HL60 cells after 24 hrs by trypan blue assay in presence of 0.789 J cm-2 of UVA light2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Pyridazinopsoralens of wide chemotherapeutic interest.
AID66160Compound was tested for the inhibition of RNA synthesis in Ehrlich cells by UV -A Irradiation relative to furoquinolinone1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID1536922Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 30 mins under dark condition measured after 5 days by coulter counting method2019Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4
Synthetically modified methoxsalen for enhanced cytotoxicity in light and dark reactions.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID380594Phototoxicity against Candida albicans at 10 ug/disk in dark
AID415931Phototoxicity against human LoVo cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues.
AID76052Compound was tested for skin photosensitizing potency in guinea pig, after exposure to 50 microg cm e-2,and 20 kJ m e-2 of UVA; strong(with edema)1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
4'-Methyl derivatives of 5-MOP and 5-MOA: synthesis, photoreactivity, and photobiological activity.
AID77713Compound was evaluated for the erythema formation; +++ means severe erythema with edema2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
A new benzoangelicin with strong photobiological activity.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID380628Phototoxicity against Microsporum canis at 10 ug/disk in presence of cool-white fluorescent light
AID426413Antitumor activity against human HeLa cells after 72 hrs by MTS assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and antitumor activity of some new xanthotoxin derivatives.
AID162564Photobinding to Poly(dA-dT)-Poly(dA-dT)-DNA in dark, determined by the shift of thermal transition temperature1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID394134Phototoxicity against Bacillus subtilis after 3 hrs irradiated with UV light by disk diffusion method2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Tetrahydrobenzo- and benzofurobenzopyrones as a new class of potential photoreagents toward DNA.
AID415937Phototoxicity against human Jurkat cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues.
AID380897Photochemical activity against denatured calf thymus DNA at 10 ug by hyperchromicity test
AID1875594Induction of melanogenesis in mouse B16 cells assessed as increase in intracellular melanin content at 50 uM incubated for 49 hrs by NaOH lysis based microplate reader assay
AID267602Antiproliferative activity against HeLa cells in presence of 0.789 J/cm2 UVA light2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New furan side tetracyclic allopsoralen derivatives: synthesis and photobiological evaluation.
AID333885Phototoxicity against Candida albicans at 10 ug/disk after irradiation with W/m'2 UV light
AID333909Genotoxicity in CHO cells assessed as chromosomal aberrations at 0.3 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID380313Phototoxicity against Streptococcus faecalis at 10 ug/disk in presence of long wave UV light
AID1466813Antibacterial activity against Staphylococcus aureus ATCC 6538 assessed as diameter of inhibition zone after 24 hrs by agar well diffusion method2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Synthesis and in vitro biological evaluation of novel coumarin derivatives containing isoxazole moieties on melanin synthesis in B16 cells and inhibition on bacteria.
AID390545Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Thiopyrano[2,3-e]indol-2-ones: angelicin heteroanalogues with potent photoantiproliferative activity.
AID316227Inhibition of p70S6K at 33 uM2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology.
AID380334Phototoxicity against Pseudomonas fluorescens at 10 ug/disk in dark
AID75482Skin Phototoxicity was tested on depilated Guinea Pigs (outbred Dunkin - Hartley strain) and erythema intensity was measured; Absent2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Novel pyrone side tetracyclic psoralen derivatives: synthesis and photobiological evaluation.
AID1209278Binding affinity to CYP2A6 (unknown origin) assessed as type 1 interaction as increase in absorbance 379 to 387 nm and decrease in 414 to 420 nm2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
AID1103215Phytotoxicity against Allium cepa (onion) assessed as accumulation of cells at prophase in root tips at 33 uM measured on day 7 of compound treatment by microscopy2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID107809The IC50-UVA is the dose of UVA light which in the presence of fixed drug concentration (20 uM) is necessary to induce a 50% inhibition of DNA synthesis by incubation at the ground state by keeping mammalian cells in the dark.1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Synthesis and biological activity of (hydroxymethyl)- and (diethylaminomethyl)benzopsoralens.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID107811The IC50-dark is the drug concentration necessary to induce a 50% inhibition of DNA synthesis by incubation at the ground state by keeping mammalian cells in the dark.1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Synthesis and biological activity of (hydroxymethyl)- and (diethylaminomethyl)benzopsoralens.
AID637774Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK as substrate after 60 mins by fluorescence quenching assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor.
AID87565Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) after exposure to UV light2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Novel pyrone side tetracyclic psoralen derivatives: synthesis and photobiological evaluation.
AID380901Photochemical activity against denatured calf thymus DNA at 10 ug after UV irradiation with 16.00 Joules/cm'2 for 180 mins by hyperchromicity test
AID378956Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio relative to TPA2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID380333Phototoxicity against Pseudomonas fluorescens at 10 ug/disk in presence of cool-white fluorescent light
AID7887Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
4'-Methyl derivatives of 5-MOP and 5-MOA: synthesis, photoreactivity, and photobiological activity.
AID589179Mechanism based inhibition of human cytochrome P450 2B6, partition ratio (value refers to P450 expressed in lymphoblastoid cells)2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID80936Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) in dark condition2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Novel pyrone side tetracyclic psoralen derivatives: synthesis and photobiological evaluation.
AID724357Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 60 mins by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID380612Phototoxicity against Sporobolomyces sp. Y138 at 10 ug/disk in dark
AID378961Inhibition of TPA-induced EBV-early antigen activation in human Raji cells2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID333849Phototoxicity against Escherichia coli at 10 ug/disk after irradiation with W/m'2 UV light
AID226322Number of nucleotides occluded by a bound furocoumarin molecule1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
4'-Methylangelicins: new potential agents for the photochemotherapy of psoriasis.
AID589228Mechanism based inhibition of human cytochrome P450 2A6 measured by coumarin 7-hydroxylation using a recombinant system2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID378962Scavenging activity against (+/-)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide-induced NO generation in human Chang liver cells2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID99418In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture irradiated at 366 nM1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
In vitro photoinduced cytotoxicity and DNA binding properties of psoralen and coumarin conjugates of netropsin analogues: DNA sequence-directed alkylation and cross-link formation.
AID333862Phototoxicity against Pseudomonas fluorescens at 10 ug/disk in dark
AID380621Phototoxicity against Fusarium sp. at 10 ug/disk in presence of long wave UV light
AID637775Inhibition of recombinant human BACE1 using Rh-EVNLDAEFK as substrate at 500 uM after 60 mins by fluorescence quenching assay2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Structure-activity relationships for naturally occurring coumarins as β-secretase inhibitor.
AID1464806Anti-proliferative activity against human L02 cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design and synthesis of new triazoles linked to xanthotoxin for potent and highly selective anti-gastric cancer agents.
AID248470Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 3.2 joule/cm**2 UVA dose2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Synthesis and photochemotherapeutic activity of thiopyrano[2,3-e]indol-2-ones.
AID1209287Binding affinity to CYP2A13 (unknown origin) assessed as type 1 interaction as increase in absorbance 379 to 387 nm and decrease in 414 to 420 nm2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
AID1756213Phototoxicity in albino guinea pig assessed as infiltration of inflammatory cells at 10 mg/kg topical treatment irradiated with 4.2 mw/cm2 UVA for 40 mins and measured after 24 hrs day of light irradiation by H and E staining based microscopic analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID423857Photo-antiproliferative activity against human HeLa cells under dark condition2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
A new psoralen derivative with enlarged antiproliferative properties.
AID415932Cytotoxicity against human K562 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues.
AID1615747Hepatoprotective activity against H2O2-induced cell death in human HepG2 cells assessed as cell viability at 10 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 24 hrs by EZ-Cytox cell viability assay (Rvb = 43.9 +/- 5.25%)2019Journal of natural products, 09-27, Volume: 82, Issue:9
Furanocoumarins from the Roots of
AID415930Phototoxicity against human LoVo cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues.
AID230577Pyrone monoadduct distribution (product resulting from photoaddition with the nucleic acid poly (dA-dT)) after 10 min irradiation at 360 nm1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
8-Methoxypsoralen-nucleic acid photoreaction. Effect of methyl substitution on pyrone vs. furan photoaddition.
AID77717Skin phototoxicity was evaluated after UVA irradiation at a dose of 0.05 (umol cm e-2) and formation of erythema was reported; Strong (with edema)2002Bioorganic & medicinal chemistry letters, May-06, Volume: 12, Issue:9
Synthesis, photobiological activity and photoreactivity of methyl-thieno-8-azacoumarins, novel bioisosters of psoralen.
AID107812The IC50-dark is the drug concentration necessary to induce a 50% inhibition of clonal growth by incubation at the ground state by keeping mammalian cells in the dark.1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Synthesis and biological activity of (hydroxymethyl)- and (diethylaminomethyl)benzopsoralens.
AID380646Phototoxicity against Trichophyton mentagrophytes at 10 ug/disk in presence of cool-white fluorescent light
AID162549Apparent binding constant was determined by ethidium displacement assay in poly (dG-dC)1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
In vitro photoinduced cytotoxicity and DNA binding properties of psoralen and coumarin conjugates of netropsin analogues: DNA sequence-directed alkylation and cross-link formation.
AID758231Cytotoxicity against human MES-SA/Dx5 cells after 96 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
New bioactive dihydrofuranocoumarins from the roots of the Tunisian Ferula lutea (Poir.) Maire.
AID134847In vivo inhibition of epidermal DNA synthesis in mouse after topical application1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
4'-Methylangelicins: new potential agents for the photochemotherapy of psoriasis.
AID1411730Inhibition of recombinant human CYP1A1 expressed in baker's yeast-derived microsomes (Sacchrosomes) at 10 uM using 7-ethoxyresorufin substrate by EROD assay relative to control2018MedChemComm, Feb-01, Volume: 9, Issue:2
Identification of karanjin isolated from the Indian beech tree as a potent CYP1 enzyme inhibitor with cellular efficacy
AID260085Inhibition of MAO-A activity2006Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3
A QSAR model for in silico screening of MAO-A inhibitors. Prediction, synthesis, and biological assay of novel coumarins.
AID423859Phototoxicity in depilated guinea pig skin assessed as formation of erythema2009Bioorganic & medicinal chemistry letters, May-15, Volume: 19, Issue:10
A new psoralen derivative with enlarged antiproliferative properties.
AID1324224Induction of melanin synthesis in mouse B16F10 cells at 50 uM after 48 hrs by spectrophotometric analysis relative to control2016Bioorganic & medicinal chemistry, 11-15, Volume: 24, Issue:22
Synthesis and biological evaluation of furocoumarin derivatives on melanin synthesis in murine B16 cells for the treatment of vitiligo.
AID81305Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HL-60 cell line2002Bioorganic & medicinal chemistry letters, May-06, Volume: 12, Issue:9
Synthesis, photobiological activity and photoreactivity of methyl-thieno-8-azacoumarins, novel bioisosters of psoralen.
AID77487Phototoxicity on guinea pig skin was calculated at concentration of 30 uM.cm-2 and UVA light dose 5 kJ.me-2. ++++ medium erythemia1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Synthesis and biological activity of (hydroxymethyl)- and (diethylaminomethyl)benzopsoralens.
AID334662Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 150 ug/plate after 72 hrs
AID380606Phototoxicity against Saccharomyces cerevisiae at 10 ug/disk in dark
AID390542Photocytotoxicity against human HT1080 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Thiopyrano[2,3-e]indol-2-ones: angelicin heteroanalogues with potent photoantiproliferative activity.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1102107Fungistatic activity against Fusarium solani assessed as growth inhibition2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID20045Dose to produce photoinduced DNA cross-link formation on isolated DNA1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
In vitro photoinduced cytotoxicity and DNA binding properties of psoralen and coumarin conjugates of netropsin analogues: DNA sequence-directed alkylation and cross-link formation.
AID55498Evaluated for photo-cross-linking of DNA1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Psoralenamines. 3. Synthesis, pharmacological behavior, and DNA binding of 5-(aminomethyl)-8-methoxy-, 5-[[(3-aminopropyl)oxy]methyl]-, and 8-[(3-aminopropyl)oxy]psoralen derivatives.
AID230576Furan monoadduct and diadduct distribution (products resulting from photoaddition with the nucleic acid poly (dA-dT)) after 10 min irradiation at 360 nm1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
8-Methoxypsoralen-nucleic acid photoreaction. Effect of methyl substitution on pyrone vs. furan photoaddition.
AID390541Photocytotoxicity against human HT1080 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Thiopyrano[2,3-e]indol-2-ones: angelicin heteroanalogues with potent photoantiproliferative activity.
AID380906Photochemical activity against denatured calf thymus DNA at in dark after 180 mins by hyperchromicity test
AID21528Solubility in water was determined1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
4'-Methylangelicins: new potential agents for the photochemotherapy of psoriasis.
AID390543Photocytotoxicity against human LoVo cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Thiopyrano[2,3-e]indol-2-ones: angelicin heteroanalogues with potent photoantiproliferative activity.
AID380891Phototoxicity against Candida albicans at 5 ug/disk after UV irradiation for 30 mins
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID380616Phototoxicity against Torula sp. at 10 ug/disk in presence of long wave UV light
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID16673Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID88691The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the presence of UVA(ultra violet A irradiated)1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
New tetracyclic analogues of photochemotherapeutic drugs 5-MOP and 8-MOP: synthesis, DNA interaction, and antiproliferative activity.
AID380309Phototoxicity against Staphylococcus albus at 10 ug/disk in dark
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID380633Phototoxicity against Microsporum cookei at 10 ug/disk in presence of long wave UV light
AID724358Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 20 mins by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID540195Antibacterial activity against Helicobacter pylori SS1 assessed as inhibition of visible growth after 96 hrs by agar dilution method2010European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
Structural modification of a specific antimicrobial lead against Helicobacter pylori discovered from traditional Chinese medicine and a structure-activity relationship study.
AID1209280Ratio of Kd for CYP2A6 (unknown origin) to Kd for CYP2A13 assessed as type 1 interaction as increase in absorbance 379 to 387 nm and decrease in 414 to 420 nm2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
AID380605Phototoxicity against Saccharomyces cerevisiae at 10 ug/disk in presence of cool-white fluorescent light
AID66153Compound was tested for the inhibition of RNA synthesis in Ehrlich cells by UV -A Irradiation1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID380895Phototoxicity against Saccharomyces cerevisiae at 5 ug/disk after UV irradiation for 30 mins
AID1102100Antifungal activity against Phomopsis obscurans assessed as growth inhibition at 300 uM after 120 hr by microplate photometric analysis2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID130473Compound was evaluated for 50% inhibition of DNA synthesis in Ehrlich ascites tumor cells by irradiation (365 nM) at 1.9 x 10e -5M incubated with [3H]thymidine at 37 degree C (p 0.05)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID211478Compound was tested for in vitro phototoxicity against nauplii of Artemia salina after UV-irradiation1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID380634Phototoxicity against Microsporum cookei at 10 ug/disk in presence of cool-white fluorescent light
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID80935Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) after exposure to UV light2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Novel pyrone side tetracyclic psoralen derivatives: synthesis and photobiological evaluation.
AID380307Phototoxicity against Staphylococcus albus at 10 ug/disk in presence of long wave UV light
AID212938Evaluated in vitro for phototoxic effect on ciliate Tetrahymena thermophila cells1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Psoralenamines. 3. Synthesis, pharmacological behavior, and DNA binding of 5-(aminomethyl)-8-methoxy-, 5-[[(3-aminopropyl)oxy]methyl]-, and 8-[(3-aminopropyl)oxy]psoralen derivatives.
AID415934Phototoxicity against human K562 cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues.
AID212936Evaluated for DNA photo-cross-linking in Tetrahymena thermophila and relative cross-linking affinity measured by the alkaline elution technique.1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Psoralenamines. 3. Synthesis, pharmacological behavior, and DNA binding of 5-(aminomethyl)-8-methoxy-, 5-[[(3-aminopropyl)oxy]methyl]-, and 8-[(3-aminopropyl)oxy]psoralen derivatives.
AID426416Antitumor activity against human HeLa cells assessed as cell viability at 50 ug/ml after 72 hrs by MTS assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and antitumor activity of some new xanthotoxin derivatives.
AID95609K+ channel blocking activity as blockade at 25 uM in Xenopus laevis Ranvier nodes1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID54251Association constant to an isolated site calf thymus DNA1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
4'-Methylangelicins: new potential agents for the photochemotherapy of psoriasis.
AID334650Toxicity in Salmonella Typhimurium T98 at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID221860Antiproliferative effect on DNA synthesis of mammalian cells upon UVA irradiation.2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Synthesis and biological evaluation of a new furo[2,3-h]quinolin-2(1H)-one.
AID333868Phototoxicity against Bacillus subtilis at 10 ug/disk in dark
AID333911Genotoxicity in CHO cells assessed as mitotic inhibition at 0.2 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID221861Antiproliferative effect on clonal growth of mammalian cells upon UVA irradiation.2002Journal of medicinal chemistry, Feb-28, Volume: 45, Issue:5
Synthesis and biological evaluation of a new furo[2,3-h]quinolin-2(1H)-one.
AID162563Photobinding to Poly(dA-dT)-Poly(dA-dT)-DNA after UV-A irradiation1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID378959Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio relative to TPA2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID208392Surviving fraction was evaluated at concentration 2 uM in T2 phage1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID666150Inhibition of PA endonuclease at 10 uM2011PloS one, , Volume: 6, Issue:5
Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID162405Apparent binding constant was determined by ethidium displacement assay in pol (dA-dT)1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
In vitro photoinduced cytotoxicity and DNA binding properties of psoralen and coumarin conjugates of netropsin analogues: DNA sequence-directed alkylation and cross-link formation.
AID451812Inhibition of calf thymus DNA topoisomerase 1 assessed as pUC19 DNA relaxation at 40 uM by gel electrophoresis2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Furanocoumarins: novel topoisomerase I inhibitors from Ruta graveolens L.
AID85579Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Pyrrolo[2,3-h]quinolinones: synthesis and photochemotherapic activity.
AID54807Compound was evaluated for the binding parameter by determining rate constant1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID333874Phototoxicity against Streptococcus faecalis at 10 ug/disk in dark
AID380617Phototoxicity against Torula sp. at 10 ug/disk in dark
AID134846In vivo inhibition of epidermal DNA synthesis in mouse after oral administration1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
4'-Methylangelicins: new potential agents for the photochemotherapy of psoriasis.
AID334656Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID230578Total radioactivity (pyrone monoadduct, furan monoadduct and diadduct resulting from photoaddition with the nucleic acid poly (dA-dT)) after 10 min irradiation at 360 nm1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
8-Methoxypsoralen-nucleic acid photoreaction. Effect of methyl substitution on pyrone vs. furan photoaddition.
AID390544Photocytotoxicity against human LoVo cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Thiopyrano[2,3-e]indol-2-ones: angelicin heteroanalogues with potent photoantiproliferative activity.
AID589180Mechanism based inhibition of human cytochrome P450 2B6, partition ratio (value refers to P450 expressed in baculovirus infected insect cells)2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID380321Phototoxicity against Escherichia coli at 10 ug/disk in dark
AID1102111Antifungal activity against Colletotrichum fragariae assessed as growth inhibition at 300 uM after 48 hr by microplate photometric analysis2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID1103220Phytotoxicity against Lactuca sativa cv. Burpee's Iceberg (lettuce) assessed as cellular leakage at 100 uM measured after incubation over 18 hr in darkness and 24 hr in light by spectrophotometry relative to control2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID20847Compound was tested for production of singlet oxygen, measured as decrease in absorbance of N,N-dimethyl-p-nitrosoaniline (RNO) at 440 nm after 5 hr of UV-A irradiation1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID426417Antitumor activity against human HeLa cells assessed as cell viability at 100 ug/ml after 72 hrs by MTS assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and antitumor activity of some new xanthotoxin derivatives.
AID234711In vivo inhibition of epidermal DNA synthesis in mouse after topical application relative to that of 8-MOP1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
4'-Methylangelicins: new potential agents for the photochemotherapy of psoriasis.
AID390540Photocytotoxicity against human JURKAT cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Thiopyrano[2,3-e]indol-2-ones: angelicin heteroanalogues with potent photoantiproliferative activity.
AID415927Phototoxicity against human NCTC-2544 cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues.
AID380592Phototoxicity against Candida albicans at 10 ug/disk in presence of long wave UV light
AID380600Phototoxicity against Rhodotorula rubra Y96 at 10 ug/disk in dark
AID380623Phototoxicity against Fusarium sp. at 10 ug/disk in dark
AID333856Phototoxicity against Pseudomonas aeruginosa at 10 ug/disk in dark
AID333886Phototoxicity against Candida albicans at 10 ug/disk in dark
AID380327Phototoxicity against Proteus mirabilis UBC 5 at 10 ug/disk in dark
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID380326Phototoxicity against Proteus mirabilis UBC 5 at 10 ug/disk in presence of cool-white fluorescent light
AID88690The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the dark1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
New tetracyclic analogues of photochemotherapeutic drugs 5-MOP and 8-MOP: synthesis, DNA interaction, and antiproliferative activity.
AID333892Phototoxicity against Saccharomyces cerevisiae at 10 ug/disk in dark
AID451813Inhibition of calf thymus DNA topoisomerase 1 assessed as pUC19 DNA relaxation by gel electrophoresis2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Furanocoumarins: novel topoisomerase I inhibitors from Ruta graveolens L.
AID76453Phototoxicity (10 mg/cm**2) was evaluated; highly toxic2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
A new benzoangelicin with strong photobiological activity.
AID380297Phototoxicity against Bacillus subtilis at 10 ug/disk in dark
AID77719The compound was tested for photo antiproliferative activity and ability to induce erythema on guinea pig skin; +++ = strong (without edema)1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
New tetracyclic analogues of photochemotherapeutic drugs 5-MOP and 8-MOP: synthesis, DNA interaction, and antiproliferative activity.
AID380892Phototoxicity against Candida albicans at 5 ug/disk after UV irradiation for 180 mins
AID1466812Antibacterial activity against Escherichia coli ATCC 11229 assessed as diameter of inhibition zone after 24 hrs by agar well diffusion method2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Synthesis and in vitro biological evaluation of novel coumarin derivatives containing isoxazole moieties on melanin synthesis in B16 cells and inhibition on bacteria.
AID380639Phototoxicity against Microsporum gypseum at 10 ug/disk in presence of long wave UV light
AID1630680Activation of mushroom tyrosinase using L-tyrosine as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins by ELISA2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and bioactivity of novel isoxazole chalcone derivatives on tyrosinase and melanin synthesis in murine B16 cells for the treatment of vitiligo.
AID380903Photochemical activity against denatured calf thymus DNA at 10 ug in dark after 30 mins by hyperchromicity test
AID724355Inhibition of soybean LOX using sodium linoleate as substrate by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID380302Phototoxicity against Micrococcus roseus UBC 289 at 10 ug/disk in presence of cool-white fluorescent light
AID390538Photocytotoxicity against human HL-60 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Thiopyrano[2,3-e]indol-2-ones: angelicin heteroanalogues with potent photoantiproliferative activity.
AID334660Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 600 ug/plate after 72 hrs
AID380303Phototoxicity against Micrococcus roseus UBC 289 at 10 ug/disk in dark
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID248195Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 3.2 joule/cm**2 UVA dose2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Synthesis and photochemotherapeutic activity of thiopyrano[2,3-e]indol-2-ones.
AID88514Compound was evaluated for cell growth inhibition against HeLa cell line by irradiation in the presence of examined compound1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
4'-Methyl derivatives of 5-MOP and 5-MOA: synthesis, photoreactivity, and photobiological activity.
AID1756214Phototoxicity in albino guinea pig assessed as necrosis at 10 mg/kg topical treatment irradiated with 4.2 mw/cm2 UVA for 40 mins and measured after 24 hrs day of light irradiation by H and E staining based microscopic analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID589223Mechanism based inhibition of human cytochrome P450 2A6 measured by coumarin 7-hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID589224Mechanism based inhibition of human cytochrome P450 2A6 measured by coumarin 7-hydroxylation using human liver microsomes2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID143813Evaluated for DNA. photo-cross-linking in cell line NHIK 3025 cross-linking affinity measured by alkaline elution technique.1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Psoralenamines. 3. Synthesis, pharmacological behavior, and DNA binding of 5-(aminomethyl)-8-methoxy-, 5-[[(3-aminopropyl)oxy]methyl]-, and 8-[(3-aminopropyl)oxy]psoralen derivatives.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID380295Phototoxicity against Bacillus subtilis at 10 ug/disk in presence of long wave UV light
AID334659Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID380645Phototoxicity against Trichophyton mentagrophytes at 10 ug/disk in presence of long wave UV light
AID1102106Antifungal activity against Botryotinia fuckeliana assessed as growth inhibition at 300 uM after 48 hr by microplate photometric analysis2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID390537Photocytotoxicity against human HL-60 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Thiopyrano[2,3-e]indol-2-ones: angelicin heteroanalogues with potent photoantiproliferative activity.
AID333867Phototoxicity against Bacillus subtilis at 10 ug/disk after irradiation with W/m'2 UV light
AID334655Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID758232Cytotoxicity against human PANC1 cells after 96 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
New bioactive dihydrofuranocoumarins from the roots of the Tunisian Ferula lutea (Poir.) Maire.
AID334651Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID390546Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Thiopyrano[2,3-e]indol-2-ones: angelicin heteroanalogues with potent photoantiproliferative activity.
AID415929Cytotoxicity against human LoVo cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues.
AID1103214Phytotoxicity against Allium cepa (onion) assessed as accumulation of cells at metaphase in root tips at 33 uM measured on day 7 of compound treatment by microscopy2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID1756212Phototoxicity in albino guinea pig assessed as erythema and edema topical treatment irradiated with 4.2 mw/cm2 UVA for 40 mins and measured after 72 hrs day of light irradiation by H and E staining based microscopic analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID88515Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HeLa cell line2002Bioorganic & medicinal chemistry letters, May-06, Volume: 12, Issue:9
Synthesis, photobiological activity and photoreactivity of methyl-thieno-8-azacoumarins, novel bioisosters of psoralen.
AID380896Phototoxicity against Saccharomyces cerevisiae at 5 ug/disk after UV irradiation for 180 mins
AID380604Phototoxicity against Saccharomyces cerevisiae at 10 ug/disk in presence of long wave UV light
AID85578Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Pyrrolo[2,3-h]quinolinones: synthesis and photochemotherapic activity.
AID267603Antiproliferative activity against HL60 cells in dark2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New furan side tetracyclic allopsoralen derivatives: synthesis and photobiological evaluation.
AID415933Phototoxicity against human K562 cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues.
AID671580Antiproliferative activity against human A431 cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
A novel tetrahydrobenzoangelicin with dark and photo biological activity.
AID467954Antiproliferative activity against mouse EAC cells assessed as ratio of ID50 of compound to ID50 of 8-methoxypsoralen2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Scoring function for DNA-drug docking of anticancer and antiparasitic compounds based on spectral moments of 2D lattice graphs for molecular dynamics trajectories.
AID1102109Antifungal activity against Fusarium oxysporum assessed as growth inhibition at 300 uM after 48 hr by microplate photometric analysis2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID81307In vitro antiproliferative activity against human promyelocytic (HL-60) cells2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
A new benzoangelicin with strong photobiological activity.
AID497312Cytotoxicity against human HL60 cells treated under dark condition after 24 hrs by trypan blue assay2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Pyridazinopsoralens of wide chemotherapeutic interest.
AID744459Inhibition of mouse brain monoamine oxidase2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease.
AID334661Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-nitroflorene-induced mutation at 300 ug/plate after 72 hrs
AID267606Phototoxicity in albino Dunkin-Hartley guinea pig skin assessed as formation of erythema with edema at 0.046 umol/cm22006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New furan side tetracyclic allopsoralen derivatives: synthesis and photobiological evaluation.
AID82835Compound was evaluated for cell growth inhibition against HL 60 cell line by irradiation in the presence of examined compound1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
4'-Methyl derivatives of 5-MOP and 5-MOA: synthesis, photoreactivity, and photobiological activity.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1103223Phytotoxicity against Lactuca sativa cv. Burpee's Iceberg (lettuce) assessed as reduction in radical length at 10 uM after 7 days by spectrophotometry relative to control2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID1536921Phototoxicity against mouse PAM212 cells assessed as cell growth inhibition preincubated for 30 mins followed by 1.28 J/cm2 UV light exposure and measured after 5 days by coulter counting method2019Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4
Synthetically modified methoxsalen for enhanced cytotoxicity in light and dark reactions.
AID1103222Phytotoxicity against Lactuca sativa cv. Burpee's Iceberg (lettuce) assessed as blunt root tips at 10 uM after 7 days by spectrophotometry relative to control2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID87566Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) in dark condition2003Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18
Novel pyrone side tetracyclic psoralen derivatives: synthesis and photobiological evaluation.
AID208549Apparent binding constant was determined by ethidium displacement assay in coliphage T4 DNA1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
In vitro photoinduced cytotoxicity and DNA binding properties of psoralen and coumarin conjugates of netropsin analogues: DNA sequence-directed alkylation and cross-link formation.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1102110Stimulation of Colletotrichum gloeosporioides growth at 30 to 300 uM after 48 hr by microplate photometric analysis2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID267601Antiproliferative activity against HeLa cells in dark2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New furan side tetracyclic allopsoralen derivatives: synthesis and photobiological evaluation.
AID380331Phototoxicity against Pseudomonas fluorescens at 10 ug/disk in presence of long wave UV light
AID380610Phototoxicity against Sporobolomyces sp. Y138 at 10 ug/disk in presence of long wave UV light
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID378957Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio relative to TPA2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1464805Anti-proliferative activity against human AGS cells after 48 hrs by MTT assay2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design and synthesis of new triazoles linked to xanthotoxin for potent and highly selective anti-gastric cancer agents.
AID333850Phototoxicity against Escherichia coli at 10 ug/disk in dark
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID724351Cytotoxicity against human 1BR3 cells assessed as cell viability at 10 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID54250Apparent binding constant was determined by ethidium displacement assay in calf thymus1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
In vitro photoinduced cytotoxicity and DNA binding properties of psoralen and coumarin conjugates of netropsin analogues: DNA sequence-directed alkylation and cross-link formation.
AID1195522Inhibition of PTP1B (unknown origin) at 20 ug/ml using pNPP substrate measured after 3 mins by colorimetric assay2015Bioorganic & medicinal chemistry letters, , Volume: 25, Issue:10
PTP1B inhibitors from stems of Angelica keiskei (Ashitaba).
AID333880Phototoxicity against Staphylococcus aureus at 10 ug/disk in dark
AID1615748Inhibition of H2O2-induced ROS accumulation in human HepG2 cells assessed as ROS generation at 10 uM preincubated for 1 hr followed by H2O2-stimulation and measured after 30 mins by H2DCFDA staining based flow cytometry (Rvb = 100 +/- 11.53%)2019Journal of natural products, 09-27, Volume: 82, Issue:9
Furanocoumarins from the Roots of
AID426412Antitumor activity against human MCF7 cells after 72 hrs by MTS assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and antitumor activity of some new xanthotoxin derivatives.
AID671578Antiproliferative activity against human HeLa cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
A novel tetrahydrobenzoangelicin with dark and photo biological activity.
AID227032Frequency of binding sites i.e., number of ligands bound per nucleotide1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
4'-Methylangelicins: new potential agents for the photochemotherapy of psoriasis.
AID380665Phototoxicity against Candida albicans at 5 ug/disk after UV irradiation for 15 mins
AID380899Photochemical activity against denatured calf thymus DNA at 10 ug after UV irradiation with 5.33 Joules/cm'2 for 60 mins by hyperchromicity test
AID135328Evaluated in vivo for its photosensitization activity, against increase in skin thickness relative to that of 8-MOP.1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Psoralenamines. 3. Synthesis, pharmacological behavior, and DNA binding of 5-(aminomethyl)-8-methoxy-, 5-[[(3-aminopropyl)oxy]methyl]-, and 8-[(3-aminopropyl)oxy]psoralen derivatives.
AID758237Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
New bioactive dihydrofuranocoumarins from the roots of the Tunisian Ferula lutea (Poir.) Maire.
AID380641Phototoxicity against Microsporum gypseum at 10 ug/disk in dark
AID211479Compound was tested for in vitro phototoxicity against nauplii of Artemia salina in daylight1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID380905Photochemical activity against denatured calf thymus DNA at in dark after 120 mins by hyperchromicity test
AID88520In vitro antiproliferative activity against human cervix adenocarcinoma (HeLa) cells2000Bioorganic & medicinal chemistry letters, Jan-17, Volume: 10, Issue:2
A new benzoangelicin with strong photobiological activity.
AID66152Compound was tested for the inhibition of DNA synthesis in Ehrlich cells by UV -A Irradiation1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID380622Phototoxicity against Fusarium sp. at 10 ug/disk in presence of cool-white fluorescent light
AID333861Phototoxicity against Pseudomonas fluorescens at 10 ug/disk after irradiation with W/m'2 UV light
AID267604Antiproliferative activity against HL60 cells in presence of 0.789 J/cm2 UVA light2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
New furan side tetracyclic allopsoralen derivatives: synthesis and photobiological evaluation.
AID333914Genotoxicity in CHO cells assessed as chromosomal aberrations at 0.02 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID1466811Antifungal activity against Candida albicans ATCC 10231 assessed as diameter of inhibition zone after 24 hrs by agar well diffusion method2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Synthesis and in vitro biological evaluation of novel coumarin derivatives containing isoxazole moieties on melanin synthesis in B16 cells and inhibition on bacteria.
AID360659Inhibition of AChE by spectrophotometry2001Journal of natural products, May, Volume: 64, Issue:5
Coumarins isolated from Angelica gigas inhibit acetylcholinesterase: structure-activity relationships.
AID1466810Induction of melanin synthesis in mouse B16 cells assessed as increase in melanin content at 50 uM after 48 hrs measured by spectrophotometric method relative to control2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Synthesis and in vitro biological evaluation of novel coumarin derivatives containing isoxazole moieties on melanin synthesis in B16 cells and inhibition on bacteria.
AID380320Phototoxicity against Escherichia coli at 10 ug/disk in presence of cool-white fluorescent light
AID333891Phototoxicity against Saccharomyces cerevisiae at 10 ug/disk after irradiation with W/m'2 UV light
AID334652Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID390539Photocytotoxicity against human JURKAT cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Thiopyrano[2,3-e]indol-2-ones: angelicin heteroanalogues with potent photoantiproliferative activity.
AID724349Cytotoxicity against human 1BR3 cells assessed as cell viability at 20 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID143814Evaluated in vitro for phototoxic effect on human cell line NHIK 3025, assay performed using threefold dilution and result reported by one dilution step.1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Psoralenamines. 3. Synthesis, pharmacological behavior, and DNA binding of 5-(aminomethyl)-8-methoxy-, 5-[[(3-aminopropyl)oxy]methyl]-, and 8-[(3-aminopropyl)oxy]psoralen derivatives.
AID1102102Antifungal activity against Phomopsis obscurans assessed as growth inhibition at 30 uM after 120 hr by microplate photometric analysis2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID380902Photochemical activity against denatured calf thymus DNA at 10 ug in dark by hyperchromicity test
AID380629Phototoxicity against Microsporum canis at 10 ug/disk in dark
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID99419In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture under the dark conditions1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
In vitro photoinduced cytotoxicity and DNA binding properties of psoralen and coumarin conjugates of netropsin analogues: DNA sequence-directed alkylation and cross-link formation.
AID77485Phototoxicity on guinea pig skin was calculated at concentration of 2 uM.cm-2 and UVA light dose 5 kJ.me-2.-- indicates no erythemia1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Synthesis and biological activity of (hydroxymethyl)- and (diethylaminomethyl)benzopsoralens.
AID380301Phototoxicity against Micrococcus roseus UBC 289 at 10 ug/disk in presence of long wave UV light
AID334654Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of acetylaminofluorene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID671581Antiproliferative activity against human A431 cells after 24 hrs by trypan blue dye assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
A novel tetrahydrobenzoangelicin with dark and photo biological activity.
AID54459Compound was evaluated for the association constant to an isolated site of DNA1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID666151Inhibition of PA endonuclease at 1 uM2011PloS one, , Volume: 6, Issue:5
Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts.
AID81634The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the presence of UVA(ultra violet A irradiated)1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
New tetracyclic analogues of photochemotherapeutic drugs 5-MOP and 8-MOP: synthesis, DNA interaction, and antiproliferative activity.
AID20131Rate constant of the photoreaction between compound and DNA.1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
4'-Methylangelicins: new potential agents for the photochemotherapy of psoriasis.
AID333873Phototoxicity against Streptococcus faecalis at 10 ug/disk after irradiation with W/m'2 UV light
AID1615746Cytotoxicity against human HepG2 cells assessed as cell viability at 10 uM incubated for 1 hr by EZ-Cytox cell viability assay2019Journal of natural products, 09-27, Volume: 82, Issue:9
Furanocoumarins from the Roots of
AID426414Antitumor activity against human HeLa cells assessed as cell viability at 5 ug/ml after 72 hrs by MTS assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and antitumor activity of some new xanthotoxin derivatives.
AID415926Cytotoxicity against human NCTC-2544 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues.
AID380898Photochemical activity against denatured calf thymus DNA 10 ug after UV irradiation with 2.67 Joules/cm'2 for 30 mins at by hyperchromicity test
AID1464804Growth inhibition of human AGS cells at 100 uM after 48 hrs by MTT assay relative to control2017Bioorganic & medicinal chemistry letters, 11-01, Volume: 27, Issue:21
Design and synthesis of new triazoles linked to xanthotoxin for potent and highly selective anti-gastric cancer agents.
AID378960Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID758230Inhibition of acetylcholinesterase (unknown origin) using acetylcholine iodide as substrate preincubated for 15 mins prior to substrate addition by spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
New bioactive dihydrofuranocoumarins from the roots of the Tunisian Ferula lutea (Poir.) Maire.
AID54115Compound was evaluated for the binding parameter by determining the number of nucleotides occluded by a bound angelicin (n)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID378958Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio relative to TPA2006Journal of natural products, Jan, Volume: 69, Issue:1
Chalcones and other compounds from the exudates of Angelica keiskei and their cancer chemopreventive effects.
AID442200Antimicrobial activity against 20 mins UV photosensitized Bacillus subtilis measured after overnight reincubation under dark condition by agar plate disc diffusion method2010European journal of medicinal chemistry, Jan, Volume: 45, Issue:1
Design, synthesis and docking studies of new furobenzopyranones and pyranobenzopyranones as photoreagent towards DNA and as antimicrobial agents.
AID1103221Phytotoxicity against Lactuca sativa cv. Burpee's Iceberg (lettuce) assessed as unbranched root tips at 10 uM after 7 days by spectrophotometry relative to control2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID333879Phototoxicity against Staphylococcus aureus at 10 ug/disk after irradiation with W/m'2 UV light
AID380315Phototoxicity against Streptococcus faecalis at 10 ug/disk in dark
AID248471Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 6.5 joule/cm**2 UVA dose2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Synthesis and photochemotherapeutic activity of thiopyrano[2,3-e]indol-2-ones.
AID426415Antitumor activity against human HeLa cells assessed as cell viability at 10 ug/ml after 72 hrs by MTS assay2009European journal of medicinal chemistry, Jul, Volume: 44, Issue:7
Synthesis and antitumor activity of some new xanthotoxin derivatives.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID671579Antiproliferative activity against human HeLa cells after 24 hrs by trypan blue dye assay2012Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11
A novel tetrahydrobenzoangelicin with dark and photo biological activity.
AID1209284Mixed inhibition of CYP2A6 (unknown origin)2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1536923Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 5 days under dark condition by coulter counting method2019Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4
Synthetically modified methoxsalen for enhanced cytotoxicity in light and dark reactions.
AID1102112Stimulation of Colletotrichum acutatum growth at 30 uM after 48 hr by microplate photometric analysis2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID95610Selectivity of K+ current blockade given by Bk/BNa in Xenopus laevis1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID54116Compound was evaluated for the frequency of the binding site that is the number of molecules bound to every nucleotide (1/n)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
6-Methylangelicins: a new series of potential photochemotherapeutic agents for the treatment of psoriasis.
AID85577Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Pyrrolo[2,3-h]quinolinones: synthesis and photochemotherapic activity.
AID333910Genotoxicity in CHO cells assessed as chromosomal aberrations at 0.3 ppm after 90 mins in dark
AID1630682Activation of tyrosinase in mouse B16F10 cells assessed as melanin production at 50 uM after 48 hrs by spectrophotometric analysis relative to control2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and bioactivity of novel isoxazole chalcone derivatives on tyrosinase and melanin synthesis in murine B16 cells for the treatment of vitiligo.
AID758236Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
New bioactive dihydrofuranocoumarins from the roots of the Tunisian Ferula lutea (Poir.) Maire.
AID380900Photochemical activity against denatured calf thymus DNA at 10 ug after UV irradiation with 10.67 Joules/cm'2 for 120 mins by hyperchromicity test
AID497313Cytotoxicity against human HL60 cells treated under dark condition after 72 hrs by trypan blue assay2010Bioorganic & medicinal chemistry, Aug-01, Volume: 18, Issue:15
Pyridazinopsoralens of wide chemotherapeutic interest.
AID380598Phototoxicity against Rhodotorula rubra Y96 at 10 ug/disk in presence of long wave UV light
AID66158Compound was tested for the inhibition of DNA synthesis in Ehrlich cells by UV -A Irradiation relative to furoquinolinone1996Journal of medicinal chemistry, Mar-15, Volume: 39, Issue:6
Angular furoquinolinones, psoralen analogs: novel antiproliferative agents for skin diseases. Synthesis, biological activity, mechanism of action, and computer-aided studies.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID333855Phototoxicity against Pseudomonas aeruginosa at 10 ug/disk after irradiation with W/m'2 UV light
AID1102096Antifungal activity against Diaporthe ampelina assessed as growth inhibition at 30 to 300 uM after 120 hr by microplate photometric analysis2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Natural fungicides from Ruta graveolens L. leaves, including a new quinolone alkaloid.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID380647Phototoxicity against Trichophyton mentagrophytes at 10 ug/disk in dark
AID380593Phototoxicity against Candida albicans at 10 ug/disk in presence of cool-white fluorescent light
AID234710In vivo inhibition of epidermal DNA synthesis in mouse after oral administration relativ to that of 8-MOP1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
4'-Methylangelicins: new potential agents for the photochemotherapy of psoriasis.
AID724354Antioxidant activity assessed as inhibition of AAPH-induced linoleic acid lipid peroxidation at 100 uM by spectrophotometric analysis2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID380325Phototoxicity against Proteus mirabilis UBC 5 at 10 ug/disk in presence of long wave UV light
AID19740In vitro photocytotoxicity is evaluated for photoinduced dose modification1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
In vitro photoinduced cytotoxicity and DNA binding properties of psoralen and coumarin conjugates of netropsin analogues: DNA sequence-directed alkylation and cross-link formation.
AID1103216Phytotoxicity against Allium cepa (onion) assessed as inhibition of mitosis in root tips at 100 uM measured on day 7 of compound treatment by microscopy2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID1209285Ratio of Ki for CYP2A6 (unknown origin) to Ki for CYP2A13 (unknown origin)2012Drug metabolism and disposition: the biological fate of chemicals, Sep, Volume: 40, Issue:9
Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
AID415935Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues.
AID248469Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 2.5 joule/cm**2 UVA dose2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Synthesis and photochemotherapeutic activity of thiopyrano[2,3-e]indol-2-ones.
AID380635Phototoxicity against Microsporum cookei at 10 ug/disk in dark
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID724350Cytotoxicity against human 1BR3 cells assessed as cell viability at 1 uM after 24 hrs by MTT assay2013European journal of medicinal chemistry, Feb, Volume: 60Syntheses and evaluation of the antioxidant activity of novel methoxypsoralen derivatives.
AID39075Photoinduced dose modification against nauplii of Artemia salina1998Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23
Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: synthesis and photoreactivity.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID334657Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 600 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID333912Genotoxicity in CHO cells assessed as chromosomal aberrations at 0.1 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID81632The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the dark1999Journal of medicinal chemistry, Oct-21, Volume: 42, Issue:21
New tetracyclic analogues of photochemotherapeutic drugs 5-MOP and 8-MOP: synthesis, DNA interaction, and antiproliferative activity.
AID334653Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of 2-aminoanthracene-induced mutation at 150 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID334658Antimutagenic activity in Salmonella Typhimurium T98 assessed as inhibition of benzo[a]pyrene-induced mutation at 300 ug/plate after 72 hrs in presence of Ames S-9 fraction
AID248194Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 2.5 joule/cm**2 UVA dose2005Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9
Synthesis and photochemotherapeutic activity of thiopyrano[2,3-e]indol-2-ones.
AID380640Phototoxicity against Microsporum gypseum at 10 ug/disk in presence of cool-white fluorescent light
AID1103219Phytotoxicity against Agrostis stolonifera assessed as mortality at 333 uM after 12 days2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
Phytotoxins from the leaves of Ruta graveolens.
AID380627Phototoxicity against Microsporum canis at 10 ug/disk in presence of long wave UV light
AID77601Phototoxicity on guinea pig skin was calculated at concentration of 4 uM.cm-2 and UVA light dose 5 kJ.me-2.+-- barely erythemia1999Journal of medicinal chemistry, Jul-29, Volume: 42, Issue:15
Synthesis and biological activity of (hydroxymethyl)- and (diethylaminomethyl)benzopsoralens.
AID380611Phototoxicity against Sporobolomyces sp. Y138 at 10 ug/disk in presence of cool-white fluorescent light
AID415936Phototoxicity against human Jurkat cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues.
AID589220Mechanism based inhibition of human cytochrome P450 2A13 measured by coumarin 7-hydroxylation and testosterone 15-hydroxylation2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID333913Genotoxicity in CHO cells assessed as chromosomal aberrations at 0.04 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins
AID380308Phototoxicity against Staphylococcus albus at 10 ug/disk in presence of cool-white fluorescent light
AID589183Mechanism based inhibition of human cytochrome P450 2A6, partition ratio2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID415928Phototoxicity against human NCTC-2544 cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay2009Bioorganic & medicinal chemistry letters, Mar-15, Volume: 19, Issue:6
Pyrano[2,3-e]isoindol-2-ones, new angelicin heteroanalogues.
AID380893Phototoxicity against Saccharomyces cerevisiae at 5 ug/disk after UV irradiation for 15 mins
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID380319Phototoxicity against Escherichia coli at 10 ug/disk in presence of long wave UV light
AID380904Photochemical activity against denatured calf thymus DNA at 10 ug in dark after 60 mins by hyperchromicity test
AID1756211Phototoxicity in albino guinea pig assessed as erythema and edema topical treatment irradiated with 4.2 mw/cm2 UVA for 40 mins and measured after 24 hrs day of light irradiation by H and E staining based microscopic analysis2021European journal of medicinal chemistry, Mar-05, Volume: 213Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,404)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901227 (51.04)18.7374
1990's546 (22.71)18.2507
2000's305 (12.69)29.6817
2010's257 (10.69)24.3611
2020's69 (2.87)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 63.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index63.45 (24.57)
Research Supply Index7.90 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index112.44 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (63.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials168 (6.63%)5.53%
Reviews90 (3.55%)6.00%
Case Studies133 (5.25%)4.05%
Observational0 (0.00%)0.25%
Other2,144 (84.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (30)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-center Randomized Phase II Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard Risk Grade II Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantat [NCT03605940]Phase 278 participants (Anticipated)Interventional2018-10-01Not yet recruiting
A Prospective, Multicenter, Single-Arm Cohort Study of Photopheresis in the Treatment of Erythrodermic MF and SS [NCT03563040]Phase 20 participants (Actual)Interventional2020-12-01Withdrawn(stopped due to Lack of feasibility)
The Effectiveness of ECP in Diffuse Cutaneous Systemic Sclerosis [NCT04986605]Phase 215 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Phase 2 Clinical Trial to Evaluate Efficacy and Safety of SM-88 Used With Methoxsalen, Phenytoin, and Sirolimus (MPS) as Maintenance Therapy Following Standard Treatments for Ewing's Sarcoma or as Salvage Therapy for Advanced Sarcomas [NCT03778996]Phase 231 participants (Actual)Interventional2020-01-03Active, not recruiting
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred [NCT03512756]Phase 2/Phase 3132 participants (Actual)Interventional2018-03-27Completed
Allogenic Hematopoietic Stem Cell Transplantation (HSCT) From a Genoidentical Donor After a Reduced Intensity Conditioning Transplantation (RICT) Followed by an Early Preventive Treatment (Day 21) With Extracorporal Photopheresis After Transplantation. [NCT00930566]Phase 1/Phase 220 participants (Anticipated)Interventional2009-04-30Recruiting
THERAKOS® CELLEX Photopheresis System as an Interventional Therapy for the Treatment of Early Stage CTCL (Mycosis Fungoides), an Open-label, Single-arm, Multi-center, Phase II Study [NCT05680558]Phase 274 participants (Anticipated)Interventional2021-05-08Recruiting
Prospective, Randomized Multicentic to Compare PUVA+IFN Alpha 2a vs PUVA Alone in Mycosis Fungoides Stages Ia, Ib or IIa. [NCT00630903]Phase 454 participants (Actual)Interventional2000-01-31Terminated(stopped due to Insufficient accrual)
Comparison of Fumaric Acid Ester-PUVA (FAE-PUVA) Versus Acitretin-PUVA (Re-PUVA) in Pustular Palmoplantar Psoriasis,a Prospective, Randomized, Controlled, Single-blinded Study [NCT00811005]Phase 320 participants (Anticipated)Interventional2008-10-31Active, not recruiting
UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A [NCT00221039]Phase 47 participants (Actual)Interventional2004-04-02Completed
"A Phase II, Multicenter, Randomized, Double-blind, Sham Pheresis-controlled, Study of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis in Patients Who Have an Inadequate Response to Disease Modifying Antirheumatic [NCT00221000]Phase 286 participants (Actual)Interventional2003-08-31Completed
UVA1 Phototherapy Versus 5-MOP UVA Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis [NCT00533195]Phase 320 participants (Anticipated)Interventional2007-10-31Completed
A Randomized Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation Versus Pentostatin and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies [NCT00402714]Phase 214 participants (Actual)Interventional2006-07-31Completed
A Muliticenter, Dose-Reandomized Evaluation Of Targretin Capsules Plus PUVA In Patients With Stage IB - IIA Cutaneous T-Cell Lymphoma [NCT00030589]Phase 20 participants Interventional2001-02-28Active, not recruiting
A Randomized Single-Blind Study of Extracorporeal Photoimmune Therapy With UVADEX in Conjunction With Standard Therapy Alone for the Treatment of Patients With Corticosteroid-Refractory, Corticosteroid-Dependent, or Corticosteroid-Intolerant Chronic Graft [NCT00054613]Phase 272 participants Interventional2002-06-30Completed
A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides [NCT00056056]Phase 393 participants (Actual)Interventional2003-01-31Terminated(stopped due to poor accrual)
A Study of Extracorporeal Photopheresis With UVADEX in the Setting of a Standard Myeloablative Conditioning Regimen for the Prevention of Graft-versus-Host Disease in Patients Undergoing an Allogeneic Bone Marrow Transplant or Peripheral Blood Stem Cell T [NCT00054600]Phase 260 participants Interventional2002-06-30Completed
A Multicenter, Open-Label, Study of Extracorporeal Photoimmune Therapy With UVADEX in the Treatment of Patients With Moderately Active Crohn's Disease Who Are Refractory or Intolerant to Immunosuppressants and/or Anti-TNF Agents [NCT00221026]Phase 225 participants (Actual)Interventional2004-12-31Completed
A Randomized, Controlled, Parallel-Group, Multicenter Study of Extracorporeal Photoimmune Therapy With THERAKOS* UVADEX* for the Treatment of Patients With Newly Diagnosed Acute Graft Versus-Host Disease [NCT00282503]Phase 319 participants (Actual)Interventional2006-01-31Terminated(stopped due to Lack of recruitment)
A Multi-center, Randomized Study on Oral 8-methoxypsoralen Plus UVA With or Without Maintenance Therapy in Mycosis Fungoides EORTC/ISCL Stage IA to IIB [NCT01686594]Phase 328 participants (Actual)Interventional2013-02-28Completed
Biomarkers in Acute Graft-Versus-Host Disease (GVHD) and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD [NCT02322190]Phase 25 participants (Actual)Interventional2014-12-20Terminated(stopped due to Due to slow/insufficient accrual and Principal Investigator left the NIH)
A Phase I Study of Photochemically Treated Donor T-Cell Supplements in HLA Haplotype Mismatched Hematopoietic Stem Cell Transplantation [NCT00005092]Phase 17 participants (Actual)Interventional1999-05-28Completed
The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex [NCT00002011]0 participants InterventionalCompleted
A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplant for the Treatment of Myelodysplastic Syndromes [NCT00045305]Phase 217 participants (Actual)Interventional2006-10-24Completed
Prophylactic Use of Extracorporeal Photopheresis (ECP) After Lung Transplantation [NCT05721079]62 participants (Actual)Interventional2017-03-01Completed
[NCT00004359]Phase 210 participants Interventional1996-02-29Completed
Open Label, Single-cohort, and Single-center Phase II Study Evaluating Tumor-specific Immunity After Extracorporeal Photopheresis in Patients With Sézary Syndrome at Single-cell Resolution [NCT05157581]15 participants (Anticipated)Observational2023-04-04Recruiting
Addition of Etanercept and Extracorporeal Photopheresis to Standard GVHD Prophylaxis in Patients Undergoing Reduced Intensity Unrelated Donor Hematopoietic Stem Cell Transplant [NCT00639717]Phase 248 participants (Actual)Interventional2009-03-31Completed
A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy With UVADEX for the Treatment of Patients With Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD) [NCT01380535]Early Phase 160 participants (Actual)Interventional2011-11-30Completed
Single-Arm Study to Assess the Efficacy of UVADEX® (Methoxsalen) Sterile Solution in Conjunction With the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients With Steroid-Refractory Acute Graft-vs-Host Disease (aGvHD) [NCT02524847]Phase 329 participants (Actual)Interventional2016-01-20Terminated(stopped due to Slow enrollment)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00045305 (6) [back to overview]Complete Response Rate
NCT00045305 (6) [back to overview]Number of Patients Who Developed Disease Progression After Achieving Complete Response
NCT00045305 (6) [back to overview]Overall Survival
NCT00045305 (6) [back to overview]Proportion of Graft Versus Host Disease
NCT00045305 (6) [back to overview]Time to Engraftment for Neutrophil
NCT00045305 (6) [back to overview]Time to Engraftment for Platelet
NCT00402714 (2) [back to overview]Incidence of Grade 2-4 Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation in Patients Randomized to Photopheresis vs. no Photopheresis
NCT00402714 (2) [back to overview]Overall Survival
NCT00639717 (3) [back to overview]Percentage of Patients Alive at 6 Months
NCT00639717 (3) [back to overview]Percentage of Patients Who Experienced Relapse by 6 Months
NCT00639717 (3) [back to overview]The Percentage of Patients That Experienced Graft Versus Host Disease
NCT01380535 (1) [back to overview]Number of Participants With an Overall Response at Week 28
NCT02322190 (3) [back to overview]Days to Overall Survival
NCT02322190 (3) [back to overview]Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).
NCT02322190 (3) [back to overview]Number of Participants With Steroid Refractory Disease Who Had Improvement and/or Resolution of Graft-versus-host Disease (GVHD) Associated Symptoms
NCT02524847 (9) [back to overview]Cumulative Dose of Daily Steroids
NCT02524847 (9) [back to overview]Duration of Response (Days) Within 16 Weeks Using Modified IBMTR Severity Index
NCT02524847 (9) [back to overview]Number of Participants Achieving Overall Response (OR) Using the Modified International Bone Marrow Transplant Registry (IBMTR) Severity Index at Week 4
NCT02524847 (9) [back to overview]Percentage of Participants Achieving Overall Response (OR) Using Modified IBMTR Severity Index at Week 12
NCT02524847 (9) [back to overview]Percentage of Participants Achieving Overall Response (OR) Using Modified IBMTR Severity Index at Week 8
NCT02524847 (9) [back to overview]Number of Participants With Adverse Events
NCT02524847 (9) [back to overview]Overall Response Rate (ORR) According to the Modified Glucksberg Criteria
NCT02524847 (9) [back to overview]Number of Patients With Liver Rated as Stage 0 - 4 Using the Modified Glucksberg Criteria
NCT02524847 (9) [back to overview]Number of Patients With Skin Rated as Stage 0 - 4 Using the Modified Glucksberg Criteria

Complete Response Rate

"Completed response is defined as:~Bone marrow evaluation: Repeat bone marrow showing < 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia (see dysplasia qualifier under peripheral blood evaluation).~Peripheral blood evaluation [absolute values must last at least 2 months] Hemoglobin >11 g/dl (untransfused, not on erythropoietin) Neutrophils (1500/mm3 (not on a myeloid growth factor)) Platelets (100,000/mm3 (not on a thrombopoetic agent)) Blasts - 0% No dysplasia. No detectable cytogenetic abnormality, if preexisting abnormality was present" (NCT00045305)
Timeframe: Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.

Interventionpercentage of participants (Number)
Arm I35.3

[back to top]

Number of Patients Who Developed Disease Progression After Achieving Complete Response

Disease free survival (DFS) was listed as a secondary endpoint in the study protocol, which would be assessed in patients who achieved complete response (CR). It was defined to be time from CR to documented progression or to death without progression. Patients without documented progression or death reported were censored at the time of last disease evaluation. However, due to the small number of patients with CR, the number of patients who developed disease progression was reported here. (NCT00045305)
Timeframe: Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.

Interventionparticipants (Number)
Arm I1

[back to top]

Overall Survival

Overall survival (OS) is defined to be the time from registration to death from any cause, with follow-up censored at the date of last contact. Kaplan-Meier method was used to estimate the distribution of OS. (NCT00045305)
Timeframe: Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.

Interventionyears (Median)
Arm I1.2

[back to top]

Proportion of Graft Versus Host Disease

Proportion of Graft versus Host Disease is calculated as number of patients with Graft versus Host Disease divided by all eligible and treated patients (NCT00045305)
Timeframe: Monthly for the first 3 months from study entry, every 3 months for the first two years from study entry thereafter and then every 6 months for years 3-5.

Interventionproportion of participants (Number)
Arm I0.412

[back to top]

Time to Engraftment for Neutrophil

Time to neutrophil engraftment is defined from date of infusion to date of neutrophil engraftment. Neutrophil engraftment is defined as ANC > 500/mm3 on two consecutive measurements. The date of engraftment is the date of the first ANC > 500/mm3. (NCT00045305)
Timeframe: Daily while hospitalized and then at least 1x/week for the first 50 days and then at least every other week until day 100.

Interventiondays (Median)
Arm I18

[back to top]

Time to Engraftment for Platelet

Time to platelet engraftment is defined from date of infusion to date of platelet engraftment. The platelet engraftment is defined as platelets > 20,000 on two consecutive measurements, at least seven days apart, without platelet transfusions in between and for at least three days before the first measurement that is over 20,000. The date of engraftment is the date of the first measurement that is over 20,000. (NCT00045305)
Timeframe: Daily while hospitalized and then at least 1x/week for the first 50 days and then at least every other week until day 100.

Interventiondays (Median)
Arm I18

[back to top]

Incidence of Grade 2-4 Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation in Patients Randomized to Photopheresis vs. no Photopheresis

(NCT00402714)
Timeframe: Day +100 following allogeneic stem cell transplant

Interventionparticipants (Number)
1 ECP and Pent/TBI1
2 Pent/TBI8

[back to top]

Overall Survival

(NCT00402714)
Timeframe: 2 years following stem cell transplant

Interventionparticipants (Number)
ECP Pento TBI2
Pento TBI5

[back to top]

Percentage of Patients Alive at 6 Months

Overall survival at 6 months (NCT00639717)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Etanercept and ECP83

[back to top]

Percentage of Patients Who Experienced Relapse by 6 Months

Relapse rate at 6 months. Relapse is defined as recurrence of disease. (NCT00639717)
Timeframe: 6 months

InterventionPercentage of patients (Number)
Etanercept and ECP8

[back to top]

The Percentage of Patients That Experienced Graft Versus Host Disease

Incidence of acute GVHD grades 2-4 and chronic GVHD in this study population (NCT00639717)
Timeframe: 6 Months

Interventionpercentage of patients (Number)
Etanercept and ECP46

[back to top]

Number of Participants With an Overall Response at Week 28

Participants with overall response included those with partial response or complete response, according to study staff who did not know which treatment they received (blinded assessment). (NCT01380535)
Timeframe: Week 28

InterventionParticipants (Count of Participants)
ECP Methoxsalen + SoC20
Standard of Care (SoC)14

[back to top]

Days to Overall Survival

Overall survival is defined as the time from study entry to end of observations/off study. (NCT02322190)
Timeframe: time from study entry to end of observations/off study, up to a year

InterventionDays (Median)
Investigator Chosen Second Line Therapy180

[back to top]

Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0).

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT02322190)
Timeframe: Date treatment consent signed to date off study, approximately 8 months and 6 days

InterventionParticipants (Count of Participants)
Investigator Chosen Second Line Therapy1

[back to top]

Number of Participants With Steroid Refractory Disease Who Had Improvement and/or Resolution of Graft-versus-host Disease (GVHD) Associated Symptoms

GVHD associated symptoms was assessed by the American Society for Bone Marrow Transplantation consensus statement. Complete Response (CR) is no residual organ specific symptoms or findings. Very Good Partial Response (VGPR) is Skin: An active erythematous rash involving < 25% of the body surface area; Liver: Persistent low-level hyperbilirubinemia, and/or Gut: Gastrointestinal function and water resorption in the colon are approaching normal. Partial Response (PR) is any improvement over baseline symptoms. Progressive disease (PD) is stable or worsening organ specific findings requiring change of therapy. (NCT02322190)
Timeframe: 7 months

InterventionParticipants (Count of Participants)
Investigator Chosen Second Line Therapy2

[back to top]

Cumulative Dose of Daily Steroids

Steroids administered from diagnosis of aGvHD to 12 Weeks after initiation of ECP treatment (NCT02524847)
Timeframe: From diagnosis of aGvHD to 12 Weeks

Interventionmg (Median)
Methoxsalen With ECP1917

[back to top]

Duration of Response (Days) Within 16 Weeks Using Modified IBMTR Severity Index

"Duration of first response is presented for patients whose disease progressed.~Duration of response is defined in the following way:~Patients whose response failed: Date at which 1st disease progression occurs - date of 1st response +1.~Patients whose response did not relapse: Date of 16 week follow-up or final assessment prior to week 16 (if patient withdrew early) - date of 1st response." (NCT02524847)
Timeframe: 16 weeks

Interventiondays (Median)
Methoxsalen With ECP13.5

[back to top]

Number of Participants Achieving Overall Response (OR) Using the Modified International Bone Marrow Transplant Registry (IBMTR) Severity Index at Week 4

"OR using the modified IBMTR Severity Index is defined as complete response (CR) + partial response (PR) as follows:~CR: complete resolution of all signs and symptoms of aGvHD in all evaluable organs without addition of next-line systemic treatment~PR: improvement of 1 stage in 1 or more aGvHD target organs without progression in others and without addition of next-line systemic treatment" (NCT02524847)
Timeframe: 4 weeks

InterventionParticipants (Count of Participants)
Methoxsalen With ECP16

[back to top]

Percentage of Participants Achieving Overall Response (OR) Using Modified IBMTR Severity Index at Week 12

"OR using the modified IBMTR Severity Index is defined as complete response (CR) + partial response (PR) as follows:~CR: complete resolution of all signs and symptoms of aGvHD in all evaluable organs without addition of next-line systemic treatment~PR: improvement of 1 stage in 1 or more aGvHD target organs without progression in others and without addition of next-line systemic treatment" (NCT02524847)
Timeframe: 12 weeks

Interventionpercentage of participants (Number)
Methoxsalen With ECP78.6

[back to top]

Percentage of Participants Achieving Overall Response (OR) Using Modified IBMTR Severity Index at Week 8

"OR using the modified IBMTR Severity Index is defined as complete response (CR) + partial response (PR) as follows:~CR: complete resolution of all signs and symptoms of aGvHD in all evaluable organs without addition of next-line systemic treatment~PR: improvement of 1 stage in 1 or more aGvHD target organs without progression in others and without addition of next-line systemic treatment" (NCT02524847)
Timeframe: 8 weeks

Interventionpercentage of participants (Number)
Methoxsalen With ECP73.7

[back to top]

Number of Participants With Adverse Events

Clinically significant changes in vital signs, laboratory values and investigations are reported as adverse events. Summary data are provided below, with details listed in the adverse events module. (NCT02524847)
Timeframe: 16 weeks

InterventionParticipants (Count of Participants)
Any serious AENon-serious TEAE at 5% thresholdDeath for any cause
Methoxsalen With ECP12173

[back to top]

Overall Response Rate (ORR) According to the Modified Glucksberg Criteria

ORR is defined as the percentage of patients who achieve an overall response after 4 weeks, 8 weeks, and 12 weeks of ECP treatment according to a scoring algorithm applied to calculate the grade of aGvHD using the modified Glucksberg Criteria. (NCT02524847)
Timeframe: 4 weeks, 8 weeks, and 12 weeks

Interventionpercentage of participants (Number)
Week 4Week 8Week 12
Methoxsalen With ECP5063.278.6

[back to top]

Number of Patients With Liver Rated as Stage 0 - 4 Using the Modified Glucksberg Criteria

Number of patients whose liver was rated as Stage 0 - 4 on the modified Glucksberg criteria - Stages are based on level of bilirubin, defined as: Stage 0 = Bilirubin < 2.0 mg/dL, Stage 1 = Bilirubin 2.0-3.0 mg/dL, Stage 2 = Bilirubin 3.1-6.0 mg/dL, Stage 3 = Bilirubin 6.1-15.0 mg/dL, and Stage 4 = Bilirubin > 15.0 mg/dL (NCT02524847)
Timeframe: at 4, 8 and 12 weeks

InterventionParticipants (Count of Participants)
Week 471942341Week 871942341Week 1271942341
Stage 2Stage 3Stage 4Stage 0Stage 1
All Participants19
All Participants1
All Participants0
All Participants13
All Participants12

[back to top]

Number of Patients With Skin Rated as Stage 0 - 4 Using the Modified Glucksberg Criteria

Number of patients whose skin was rated as Stage 0 - 4 using the modified Glucksberg criteria based on the Graft versus Host Disease (GvHD) rash - Stages are defined as 0=No GvHD rash, 1=Maculopapular rash on <25% body surface area (BSA), 2=Maculopapular rash on 25-50% BSA, 3=Maculopapular rash on >50% BSA, and 4=Generalized erythroderma plus bullous formation, which are blisters bigger than 5 mm across (NCT02524847)
Timeframe: at 4, 8 and 12 weeks

InterventionParticipants (Count of Participants)
Week 471942341Week 871942341Week 1271942341
Stage 0Stage 1Stage 2Stage 3Stage 4
All Participants9
All Participants8
All Participants3
All Participants11
All Participants5
All Participants1
All Participants10
All Participants2
All Participants0

[back to top]